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ABSTRACT

Virus-like particles (VLPs) of MS2 bacteriophage possess a variety of
characteristics that enable their use in biomedical and materials science applications.
MS2 VLPs are perfectly monodisperse and possess a highly regular periodic structure.
Their protein capsids can be modified in precise locations via chemical conjugation or
genetic display of peptides, and their interior volumes can be readily loaded with a
variety of non-genomic materials by taking advantage of their ability to self-assemble in
the presence of RNA and RNA-modified cargos. Using peptides identified by
filamentous phage display, I have demonstrated the utility of MS2 VLPs as targeted
nanocarriers capable of highly specific delivery of various therapeutic and imaging
agents to human cancer cells in vitro and as templates in the synthesis of novel types of
nanomaterials, including self-assembled hexagonal close-packed arrays and nanoparticles
iv

with greatly enhanced surface plasmonic properties. Multivalent peptide display on MS2
VLPs greatly enhances their affinity for target cells (e.g. hepatocellular carcinoma),
providing the specificity necessary to deliver various therapeutic agents, including
chemotherapeutic drugs, siRNA cocktails, and the A-chain of ricin toxin, to cancer cells
without affecting the viability of normal cells (e.g. hepatocytes, endothelial cells, and
immune cells). siRNA cocktails and ricin A-chain, when delivered to cancer cells via
targeted VLPs, induce apoptosis within 48 hours at concentrations less than 10 pM and
100 fM, respectively. Multivalent peptide display on MS2 VLPs also promotes the
deposition of remarkably thin, conformal coatings of gold. By encapsidating 16-nm
quantum dots within VLPs prior to the metallization of their exterior surface, I hope to
create a new class of core-shell nanoparticles with greatly enhanced fluorescence
properties. Finally, evaporation-induced self-assembly of MS2 VLPs enables the
formation of highly ordered hexagonal close-packed monolayers, the long-range
periodicity of which can be measured using in situ GISAXS. Assembling the core-shell
nanoparticles into a 2D array potentially enables construction of a hybrid plasmonic
waveguide that allows optical energy to be transported from one location to another
beyond the diffraction limit. For solar energy harvesting applications, the absorption
coefficient of quantum dots is enhanced by the metal plasmonic shell, potentially
enabling the development of an ultra-thin solar cell.
I have, additionally, developed a porous silica nanoparticle-supported lipid bilayer
(‘protocell’) for targeted delivery applications. Protocells combine enhanced specificity,
stability, and cargo capacity when compared to similarly-sized liposomes. They can,
additionally encapsulate and deliver multicomponent cargos. Due to their unique
v

biophysical features, protocells loaded with drug cocktails (e.g. doxorubicin, 5fluorouracil, and cisplatin) are able to kill drug resistant cancer cells 107-fold more
effectively than FDA-approved liposomal doxorubicin (Doxil®).
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INTRODUCTION
Biological materials can direct the formation of complex inorganic materials (1,
2), while organic and inorganic materials can influence cellular behavior (e.g. sensing,
dormancy, drug resistance, etc.) and induce cell death (3, 4).

Although composite

materials with biotic and abiotic elements have been developed for a wide variety of
applications, I will focus on the use of bio-nano interfaces in two related research
avenues: (1) the use of protein and inorganic nanoparticles for targeted delivery of
multicomponent cargos to human cancer and (2) the self-assembly of protein
nanoparticles into well-ordered structures that can be replicated in any arbitrary inorganic
material via peptide-directed nucleation and growth.
A plethora of inorganic, organic, and biological materials have been developed
for a vast number of medical applications, including biosensing (2), tissue regeneration
(5), directed stem cell differentiation (6), single cell isolation and probing(3), lab-on-achip analysis of complex biofluids (7), high throughput DNA sequencing (8), vaccine
development and other types of immunomodulation (9, 10), targeted delivery of
therapeutic and diagnostic agents to cancer, virally-infected cells, and pathogenic bacteria
(4, 11, 12), and controlled release of protein drugs and opioids (13-15). Nanoparticles
composed of lipids (e.g. liposomes), polymers (e.g. PEG nanoparticles, PAMAM
dendrimers, etc.), proteins (e.g. viruses, bacteriophages, virus-like particles, etc.), or
inorganic materials (e.g. mesoporous silica, gold, etc.) have been used for passive and
active targeting of drugs to a variety of cells, including cancer and pathogenic bacteria, as
well as controlled release of encapsulated cargo over several days or weeks (4, 16, 17).
1

Liposomes and polymeric nanoparticles constitute the majority of nanoparticle-based
delivery systems currently in FDA trials and have been utilized to encapsulate a variety
of cargos and target a variety of cancers (18). More recently, porous inorganic particles
have been used to deliver higher concentrations of cargo in a controllable fashion (19),
while gold nanoparticles and nanoshells have been utilized to induce localized
hyperthermia upon infrared radiation (20). Most state-of-the-art nanocarriers suffer from
limited specificity, stability, and/or cargo capacity, however. To this end, I developed the
protocell (21-23), a porous silica nanoparticle-supported lipid bilayer, for use in targeted
delivery applications. The protocell combines enhanced specificity and stability with the
ability to simultaneously encapsulate and deliver high concentrations of chemically
disparate therapeutic and diagnostic agents. Protocells are, furthermore, non-toxic, nonimmunogenic, and cost-effective to manufacture in large quantities (~0.5¢ per dose). I
have also adapted virus-like particles of MS2 bacteriophage for use in targeted delivery
applications. MS2 VLPs naturally self-assemble in the presence of RNA and can,
therefore, be rapidly loaded with therapeutic RNAs, as well as any cargo that can be
surface-modified with nucleic acids. Furthermore, targeting peptides and scFvs can be
chemically conjugated or genetically inserted into the protein capsid of MS2 VLPs to
promote selective cargo delivery. Importantly, MS2 VLPs are the first example of a
platform that integrates the random peptide display capabilities of filamentous phage with
the cargo capacity of a hollow capsid. Protocells and virus-like particles individually
address numerous challenges associated with targeted delivery and can potentially be
used as universal nanocarriers capable of delivering multicomponent cargos to any
arbitrary type of cancer.
2

Globular proteins, as well as viruses, bacteriophages, and virus-like particles are
highly monodisperse and can be assembled into well-ordered two- and three-dimensional
structures using a variety of evaporation-driven techniques (24, 25). I have employed a
horizontal convective assembly technique to promote the formation of hcp monolayers
from a colloidal suspension containing virus-like particles of MS2 or Qβ bacteriophage. I
monitored the time-dependent structural evolution of these monolayers via in situ
GISAXS and modulated their long-range order by varying the coating conditions that
affect particle-particle interactions and particle-substrate interactions. These selfassembled structures can be replicated in any inorganic material of interest via
modification of the protein surface with peptides that promote nucleation and growth of a
specific material. Phage display has been utilized to identify peptides that bind to a wide
variety of inorganic materials. These peptides are capable of selectively binding to the
target material and can recognize different lattice types (1). Furthermore, peptides that
exist in an unbound form can promote the formation of nanoparticles from an appropriate
precursor solution (26). Peptides conjugated to a surface can direct the organization of
pre-formed nanoparticles into hierarchical structures and can, additionally, promote
deposition of various materials on bacteriophage and viral surfaces(27). I have modified
the surfaces of MS2 VLPs with gold-binding peptides that, when displayed in high
densities, promote the deposition of thin, conformal gold coatings on the VLP surface. By
encapsulating different materials, such as quantum dots, within the interior volume of
MS2 VLPs prior to their metallization, I hope to create ultra-bright plasmonic
nanoparticles, as well as metamaterials with unique optical and electrical properties.
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CHAPTER 1

Protocells – A Universal Nanocarrier for Targeted Delivery of
Multicomponent Cargos to Cancer

It has been long recognized that the pharmacological properties of ‘free’ drugs
can be improved through their targeted delivery using nanocarriers1. Although numerous
types of cancer therapeutics that employ passively-targeted liposomes, polymers, or
proteins for drug encapsulation or complexation are commercially-available2, few
clinically-approved drugs that selectively target diseased cells via specific biomolecular
interactions yet exist1. Here we report the development of porous nanoparticle-supported
lipid bilayers (protocells)3-5, a new class of targeted nannocarriers which, due to a unique
set of biophysical properties, simultaneously addresses multiple challenges associated
with targeted delivery, including specificity, a high capacity for disparate types of cargo,
controllable cargo release, stability, solubility, biocompatibility, and lack of
immunogenicity1. Protocells, when modified with a targeting peptide (SP946) that binds
to human liver cancer (hepatocellular carcinoma, or HCC), exhibit a 10,000-fold greater
affinity for HCC than for normal human hepatocytes, endothelial cells, and immune cells.
We have loaded protocells with multicomponent cargos including therapeutics (e.g.
drugs, siRNA, and protein toxins) and diagnostic agents (e.g. quantum dots).
Significantly, due to the enormous cargo capacity of the high-surface-area nanoporous
core combined with the enhanced targeting efficacy enabled by the supported lipid
bilayer’s remarkable fluidity, as few as one protocell loaded with a chemotherapeutic
drug cocktail can kill an HCC cell with induced multiple drug resistance, representing a
6

106-fold improvement over liposomal doxorubicin7.

Due to their combination of

specificity, stability, and enhanced cargo capacity, we propose that protocells can serve
as universal nanocarriers capable of delivering a high payload of therapeutic and
diagnostic agents directly to human cancer cells with minimal systemic toxicity.
Targeted delivery of drugs encapsulated within nanocarriers can potentially
ameliorate a number of problems exhibited by conventional ‘free’ drugs, including poor
solubility, limited stability, rapid clearing, and lack of selectivity, which can result in
non-specific toxicity to healthy cells and prevent the dose escalation necessary to
eradicate diseased cells8. Passive targeting schemes, which rely on the enhanced
permeability of the tumor vasculature to promote accumulation of nanocarriers (the socalled enhanced permeability and retention, or EPR, effect) overcome many of these
problems, but the lack of cell-specific interactions needed to induce nanocarrier
internalization can result in drug expulsion and induction of multiple drug resistance
(MDR)9. Additionally, not all tumors exhibit the EPR effect,10 and passively-targeted
nanocarriers are no more effective at treating blood cancers then free drugs11. Selective
targeting strategies employ ligands (e.g. peptides, monoclonal antibodies, aptamers,
vitamins, etc.) conjugated to the nanocarrier surface that specifically interact with
receptors expressed on the cell surface of interest12. This strategy requires that receptors
are highly over-expressed by the target cell (104-105 copies/cell) relative to normal cells1.
Displaying multiple copies of the targeting ligand on the nanocarrier surface promotes
collective, multivalent binding effects that result in enhanced affinity13 and more efficient
drug delivery through receptor-mediated internalization pathways, which help circumvent
the efflux mechanisms that contribute to MDR14. However, it has been observed that
targeting ligands can also increase non-specific interactions, resulting in rapid
entrapment of nanocarriers by such barriers as the walls of blood vessels and phagocytic
7

cells that reside in the liver and spleen

15

. Modifying the nanocarrier surface with

hydrophilic, shielding polymers (e.g. polyethylene glycol, or PEG) reduces non-specific
interactions with serum proteins and macrophages of the reticuloendothelial system but
also invariably diminishes targeting specificity15.
Liposomes are the most extensively studied class of nanocarriers due to their low
inherent toxicity and immunogenicity, as well as the relative ease with which their
surfaces can be modified with PEG to improve circulation times12. However, nearly ten
years after FDA-approval of liposomal doxorubicin, there remain significant challenges
to the successful implementation of liposomes as targeted nanocarriers. Liposomes and
other targeted nanocarriers must be able to simultaneously achieve high targeting
specificity and delivery efficiency, while avoiding entrapment by the body’s defences.
Other desirable characteristics include a high capacity for disparate types of therapeutic
and diagnostic agents, the ability to controllably release encapsulated cargo upon
internalization within the target cell, stability, solubility, and lack of immunogenicity1. In
some cases, it is also desirable to direct the intracellular targeting of delivered cargo in
order to maximize therapeutic efficacy 16.
Here we report the development of a novel targeted nanocarrier: the ‘protocell,’ a
porous nanoparticle-supported lipid bilayer3-5 (see Figure 1) that addresses many
limitations associated with state-of-the-art nanocarriers. Fusion of liposomes to a
spherical, high-surface-area nanoporous silica core followed by modification of the
resulting supported lipid bilayer (SLB) with PEG and multiple copies of targeting and
fusogenic peptides creates a unique construct that, in comparison to liposomes, maintains
enhanced selectivity and stability while enabling the targeted delivery and controlled
release of high concentrations of multicomponent cargos (see Figure 2b). Importantly, the
nanoporous silica core suppresses the large-scale bilayer fluctuations that limit liposome
8

stability while also enhancing bilayer fluidity compared to that of either unsupported
bilayers (i.e. ‘empty’ liposomes) or bilayers supported on solid silica particles. This
synergistic combination of properties enables high targeting specificity with a minimal
number of targeting ligands, which is crucial to reduce non-specific binding and
minimize immunogenicity.
a

b

c
Lipid & Silica

Doxorubicin

siRNA

Merge

Figure 1. Features of the porous nanoparticle-supported lipid bilayer. (a) A schematic of the protocell,
depicting the disparate types of therapeutic and diagnostic agents that can be loaded within the nanoporous
silica core. Targeting and fusogenic peptides can be conjugated to phosphatidylethanolamine (DOPE or
DPPE), present in the SLB at 1-10 wt%, via a heterobifunctional crosslinker with a PEG spacer arm. The
SLB is composed of either fluid (DOPC) or non-fluid (DPPC) zwitterionic lipids with 30 wt% cholesterol
and 5 wt% PEG-2000 PE to enhance colloidal stability and decrease non-specific interactions. (b)
Cryogenic TEM image of the protocell, showing the nanoporous core and the 5-nm SLB (bracketed by
arrows). Scale bar = 25 nm. (c) Fluorescence microscopy image of protocells formed on large porous cores
to enable imaging, showing NBD-labeled lipid (green) fully encapsulating the Alexa Fluor 405®-labeled
silica core (blue), which is loaded with doxorubicin (red) and Alexa Fluor 647®-labeled siRNA (white).
Scale bar = 5 µm.
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To demonstrate the unique biophysical properties of protocells, Figure 2a shows
temperature-dependent fluorescence recovery after photobleaching (FRAP) results for a
DPPC (transition temperature, Tm = 41˚C) bilayer supported on a nanoporous or solid
silica particle. We observe that the photobleached region begins to recover at 35°C (±
1°C) for the nanoporous SLB compared to 41°C (± 1°C) for both the solid SLB and
unilamellar liposomes17: in effect the nanoporous support suppresses the transition
temperature of DPPC by 6°C. We propose that the underlying 3D porosity of the support
(composed of nanoscopic patches of silica and water) modulates the local packing density
of lipid head groups, thereby increasing fluidity without appreciably changing the
average packing density (determined by us previously using neutron reflectivity18). This
effect is not observed for bilayers supported on either solid surfaces or silica thin films
with 2D nanopores oriented parallel to the substrate surface (where Tm = 41˚C as
commonly reported).

As illustrated in Figure 2b, increased SLB fluidity enables a

targeting peptide, when displayed in low densities on the SLB, to bind multivalently to
surface receptor(s) expressed by the cancer cell of interest (HCC in this case);
cooperative, multivalent interactions are crucial to achieve high specific affinity and to
direct receptor-mediated endocytosis of protocells. The ability of targeting peptides to be
recruited to a cancer cell surface when displayed on a nanoporous SLB is vividly
demonstrated in Figure 2c. NBD-labeled DOPC (Tm = -20˚C) or DPPC liposomes were
fused to a planar nanoporous substrate (with a 3D pore structure identical to that of the
protocell core) and modified with a low density (~0.015 wt%) of Alexa Fluor 647®labeled SP94 peptides (H2N-SFSIILTPILPL-COOH, identified via filamentous phage
display to have an affinity for unknown receptor(s) expressed by human HCC6). Upon
addition of an HCC cell line (Hep3B) to the supported planar bilayers at 25°C, we
10

observed rapid (1-2 minutes) recruitment of SP94 peptides to the cancer cell surface for
the fluid DOPC bilayer with no measurable recruitment for the solid DPPC bilayer. As
shown in Figure 2d, SP94-targeted DOPC protocells are efficiently endocytosed by
Hep3B but not by normal (i.e. untransformed) hepatocytes.

Figure 2. Biophysical characteristics of protocells that promote high affinity surface binding and
internalization by HCC. (a) Temperature-dependent FRAP of NBD-labeled DPPC bilayers (green)
supported on nanoporous (○) or solid (●) spherical silica particles. Inset: normalized fluorescence recovery
in the photobleached region (blue circle) was determined by dividing the fluorescence intensity (FI) in
region of interest 1 (ROI1) by the FI in ROI2. Scale bar = 5 µm. (b) DOPC protocells bind to HCC with
high affinity due to recruitment of SP94 targeting peptides to the cell surface (step 1), become internalized
via receptor-mediated endocytosis (step 2), and release their cargo into the cytosol upon endosome
acidification and protonation of the H5WYG fusogenic peptide (step 3). Cargos modified with a NLS are
transported through the nuclear pore complex and become concentrated in the nucleus (step 4). (c) SP94
peptides (white) can be recruited to the surface of a Hep3B cell (cytosol = red, nucleus = blue) at 25°C
when displayed on a planar nanoporous SLB (green) composed of DOPC (○) but not DPPC (●). Inset scale
bars = 5 µm. (d) and (e) DOPC protocells (lipid = red, silica = white) that display a low density of SP94 are
endocytosed by Hep3B (d; cytosol = green, nucleus = blue) but not by hepatocytes (e). Scale bars = 10 µm.
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To demonstrate that specific affinity for HCC is dramatically influenced by
multivalent binding effects and that these effects can be enhanced when peptides are
displayed on a fluid SLB, we conjugated various densities of SP94 (1 to 2048 peptides
per particle, on average) to DOPC or DPPC protocells and liposomes and determined the
resulting dissociation constants (Kd) using flow cytometry (low Kd values correspond to
high specific affinities; see Supplementary Figure 1 for details). Figure 3a demonstrates
that SP94-targeted DOPC protocells have a high specific affinity (Kd < 1 nM) for Hep3B
and that, over the range of 6 to 2048 peptides per particle, their Kd values are consistently
low (0.94 – 0.08 nM) and relatively independent of peptide density. DOPC protocells
modified with ~240 copies of the SP94 peptide have a Kd (~0.1 nM) that is 104-fold
lower than the Kd values of SP94-targeted protocells for various control cells, including
human hepatocytes (see Figure 3b), endothelial cells (HUVECs), and immune cells
(PBMCs and B- and T-lymphocytes), 2000-fold lower than the Kd of free SP94 for
Hep3B, and nearly 50,000-fold lower than the Kd of unmodified protocells for Hep3B
(see Supplementary Figure 2). The influence of SLB fluidity on multivalent binding and
specific affinity is clearly illustrated by a comparison of DOPC and DPPC protocells
modified with various concentrations of SP94 (see Figure 3a). At high SP94 densities (≥
240 peptides/particle), multivalent effects can be realized even when peptides are
displayed on solid DPPC SLBs. At lower SP94 densities, however, the Kd values of
DPPC protocells increase dramatically with decreasing peptide density and approach the
Kd of the monovalent peptide. This result is due to the kinetic hindrance experienced by
peptides conjugated to solid SLBs, which limits peptide recruitment to the cancer cell
surface and decreases the specific affinity of DPPC protocells in a peptide densitydependent fashion. The Kd values of protocells are consistently lower than those of
similarly-sized liposomes (~120-nm in diameter) at all SP94 densities (see Figure 3a), a
result we attribute to the enhanced fluidity of the protocell SLB combined with the ability
12

of the nanoporous core to suppress the large-scale bilayer fluctuations that likely act as a
steric barrier to multivalent binding of peptides displayed on liposomes to the Hep3B
surface. At a density of ~6 peptides per particle, DOPC protocells have a 200-fold lower
Kd than DOPC liposomes, the significance of which is demonstrated by our observation
that reducing peptide density greatly decreases non-specific binding of DOPC and DPPC
protocells and liposomes to normal hepatocytes (see Figure 3b). Therefore, protocells that
possess a fluid SLB are uniquely able to selectively target HCC at low SP94 densities, as
evidenced by the 104-fold difference between their specific affinity for Hep3B and their
non-specific interaction with hepatocytes. If sub-nanomolar affinity is undesirable (e.g.
results in reduced tumor penetration), the Kd values of SP94-targeted protocells can be
precisely modulated by incorporating various amounts of fluid and non-fluid lipids into
the SLB (see Supplementary Figure 3).
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a

b

c

d

Figure 3. The specific affinity and cytotoxicity of protocells, as compared to liposomes. (a) and (b)
Dissociation constants (Kd) of SP94-targeted protocells and liposomes for Hep3B (a) and hepatocytes (b) as
a function of the average number of SP94 peptides per particle (average SP94 wt% is in parentheses). K d
values are shown for DOPC protocells (■), DPPC protocells (■), DOPC liposomes (■), and DPPC
liposomes (■). DOPC protocells modified with a low density of SP94 have a maximal affinity for Hep3B
and a minimal affinity for hepatocytes. All surface binding experiments were conducted at 4°C to prevent
endocytosis of protocells and liposomes. (c) Capacity and cytotoxicity of DOX-loaded protocells and
liposomes. Left axis: the absolute (■) and effective capacities (■) of DOPC protocells, DSPC liposomes,
and DOPC liposomes for DOX. Absolute capacity is defined as the concentration of DOX that can be
physically encapsulated within 1010 particles, while effective capacity is the concentration of DOX that is
released upon endocytosis by HCC in a form capable of intercalating nuclear DNA. Right axis: the number
of DOX-loaded protocells or liposomes (■) that must be added to 106 MDR Hep3B to kill 90% of the cells
in the population (LC90) within 24 hours. See Supplementary Figure 9 for the LC90 values of free DOX and
DOX-loaded protocells. (d) The number of MDR Hep3B (■) and hepatocytes (■) that remain viable after
exposure to 10 µM of free DOX, protocell-encapsulated DOX, or liposomal DOX for 24 hours. Due to
their enhanced specificity, stability, and capacity, protocells are cytotoxic to MDR Hep3B but not
hepatocytes. Sytox® Green nucleic acid stain and Alexa Fluor 647®-labeled annexin V were used to
distinguish viable (double-negative) from non-viable (single- or double-positive) cells. All error bars
represent 95% confidence intervals (1.96 σ) for n = 5 (a and b) or n = 3 (c and d).
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As illustrated schematically in Figure 2b, multivalent binding of SP94 to HCC
surface receptor(s) initiates receptor-mediated endocytosis, an internalization pathway
that helps to circumvent MDR19. The confocal microscopy images in Figures 2d and 2e
demonstrate that SP94-targeted DOPC protocells are internalized by Hep3B but not by
hepatocytes. To demonstrate that high affinity surface binding followed by receptormediated endocytosis enables targeted delivery of multicomponent cargos, we
encapsulated various therapeutic and diagnostic agents (see Figure 1a) within the
protocell core by simply soaking the nanoporous particles in a solution of the desired
cargo prior to fusion of DOPC liposomes and conjugation of SP94 peptides to the SLB.
We determined that the SP94 peptide directs protocells to lysosomes upon endocytosis by
HCC (see Supplementary Figure 4); in order to prevent degradation of sensitive cargo,
we further modified the SLB with a histidine-rich fusogenic peptide (H5WYG, H2NGLFHAIAHFIHGGWHGLIHGWYG-COOH20)

that

promotes

endosomal

escape

without affecting the integrity of the plasma membrane. As illustrated in Figure 2b,
delivery of encapsulated cargo to HCC is achieved via the following successive steps: (1)
DOPC protocells bind to the surface of HCC cells via the interaction between SP94
(magenta) and unknown receptor(s) overexpressed by HCC. Peptide recruitment to the
cell surface promotes the multivalent effects that increase specificity. (2) Protocells are
endocytosed by HCC cells, and endosome acidification destabilizes the SLB (see
Supplementary Figure 5), thereby enabling encapsulated cargo to diffuse out of the
nanoporous core. Protonation of imidazole moieties (pKa = 6.0) in the fusogenic peptide
(blue) initiates osmotic swelling and membrane destabilization of endosomes via the
‘proton sponge’ mechanism. (3) Endosome disruption enables protocell components and
cargo to become distributed in the cytosol of the HCC cell. (4) Finally, cargo modified
with a nuclear localization sequence (M9 domain of heterogeneous nuclear
ribonucleoprotein

A1,
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H2N-

NQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY-COOH21)

become

concentrated in the nucleus. By encapsulating fluorescent surrogates (similar in size and
charge to therapeutic or diagnostic agents of interest) within protocells prepared with
fluorescently-labelled SLBs and nanoporous cores, the various stages involved in cargo
delivery can be visualized by hyperspectral confocal fluorescence microscopy (Figure 4).
As evidenced by the appearance of punctuate regions containing co-localized lipid, silica,
and cargo, protocells are rapidly endocytosed (t½ = 15 minutes) by Hep3B cells (see
Figure 4a) and reach a saturating intracellular concentration (~500 protocells per Hep3B
cell) within 2 hours. Approximately 4 hours after endocytosis, the lipid and silica
moieties of the protocell, as well as the four model cargos become distributed throughout
the cytosol of Hep3B cells (see Figure 4b), and, within 24 hours, cargos modified with
the NLS are targeted to the nuclei (see Figure 4c).
We have utilized the above sequence of events to deliver high payloads of various
cytotoxic agents, including drugs and drug cocktails, siRNA cocktails (see
Supplementary Figure 6), and protein toxins (see Supplementary Figure 7) to Hep3B
without affecting the viability of control cells. Due to the large pore volume (~50%) and
high surface area (>1000 m2/g) of their nanoporous cores, protocells have a 1000-fold
higher capacity for the chemotherapeutic drug, doxorubicin (DOX) than similarly-sized
liposomes loaded via an ammonium phosphate gradient-based approach (see Figure 3c,
left axis). Additionally, protocells exhibit long-term stability that is independent of the
SLB composition: given that their SLBs remain fully intact, DOPC protocells release a
negligible amount of DOX when maintained in neutral pH buffer or complete growth
medium at 4°C for > 3 weeks (see Supplementary Figure 8). Conversely, DOPC
liposomes release nearly all of their encapsulated DOX within 72 hours. Therefore, the
fluid lipids that enable selective targeting at low peptide densities (necessary to minimize
16

non-specific binding and uptake by the body’s defences) cannot be used in liposomal
drug formulations, since pre-mature release of encapsulated cargo results in non-specific
toxicity to healthy cells (see discussion of Figure 3d).
a
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Figure 4. Delivery of multicomponent cargos to the cytosol and nuclei of HCC cells. Hyperspectral
confocal fluorescence microscopy was employed to individually track the lipid (red) and silica (yellow) of
the protocell, as well as four model types of cargo (green = calcein, a low molecular weight drug mimic;
magenta = a double-stranded DNA oligonucleotide, which acts as a siRNA mimic; orange = red fluorescent
protein, a protein toxin mimic; teal = far red-fluorescent quantum dots, a model nanoparticle) within the
cytosol (purple) and nuclei (blue) of Hep3B cells as a function of time. (a) Within 15 minutes of exposing
Hep3B to protocells loaded with the multicomponent mixture, the lipid, silica, and cargos have a punctate
appearance, indicating that protocells are localized within endosomes. (b) Within 4 hours, the H5WYG
peptide promotes endosomal escape, thereby releasing the lipid, silica, and cargos into the cytosol of the
Hep3B cells. (c) Within 24 hours, calcein and the dsDNA oligonucleotide, both of which are modified with
a NLS, become concentrated in the nucleus, while the RFP and quantum dots remain largely localized in
the cytosol. Scale bars = 20 µm.
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The combination of properties unique to targeted protocells solve the challenge of
maintaining high targeting specificity and inducing rapid cytotoxicity of target cells,
while avoiding collateral damage to normal cells. Figure 3c (right axis) plots the number
DOPC protocells and liposomes, loaded with DOX, modified with a low peptide density
(0.015%), and stabilized with PEG, needed to kill 90% of Hep3B with induced MDR
5

(LC90). We observe that 10 fewer protocells are necessary to achieve the LC90 value
than for corresponding liposomes. Figure 3d shows the percentage of Hep3B and
hepatocytes that remain viable after exposure to 10 µM of DOX (in a ‘free’ form or
encapsulated within protocells or liposomes) for 24 hours. Here we observe that DOXloaded protocells maintain greater than 90% hepatocyte viability, while killing over 95%
of MDR Hep3B. By comparison, liposomes are less efficient at killing Hep3B and induce
significant cytotoxicity of normal cells. We attribute these striking differences to the
several orders of magnitude higher capacity (Figure 3c) and binding affinity (Figure 3a)
of DOPC protocells, which combine synergistically to provide dramatic improvements in
selective cytotoxicity, as well as the low density of targeting peptides and long-term SLB
stability, which reduce non-specific binding and toxicity to normal cells. Importantly,
protocells can also be loaded with multicomponent cargos. Figures 3c and 3d show that,
when loaded with a cocktail of DOX, 5-fluorouracil, and cisplatin (a chemotherapeutic
drug cocktail known to be particularly effective against HCC22), as few as one SP94modified protocell is sufficient to kill a Hep3B cell with induced MDR while maintaining
> 90% hepatocyte viability.
In summary, we have demonstrated that protocells bearing the SP94 targeting
peptide combine the high specificity, enhanced cargo capacity, and long-term stability
necessary to deliver a variety of therapeutic and diagnostic agents to cancer cells with
minimal side effects. The combined attributes of protocells enable their use as a universal
18

nanocarrier that simultaneously addresses the complex requirements of multicomponent
targeted delivery, the successful implementation of which is critical to effectively combat
cancer.

Methods Summary
Nanoporous silica particles were synthesized and characterized as described previously
by us (see Supplementary Figure 10)23, and particles larger than 200-nm in diameter were
removed via differential centrifugation or size-exclusion chromatography (see
Supplementary Figure 10b and 10f). Protocells were formed by fusing 120-nm liposomes
to the nanoporous core as reported previously3-5, and the composition of the SLB was
optimized to reduce non-specific binding and to mitigate the cytotoxicity associated with
cationic and, to a lesser extent, anionic lipids (see Supplementary Figures 11 and 12)24.
Zwitterionic lipids, such as DOPC or DPPC, with 5 wt% phosphatidylethanolamine (PE),
5 wt% PEG-2000 PE, and 30 wt% cholesterol were used in all further studies. The size of
the nanoporous core was also optimized to attain a balance between achievable cargo
capacity and the rate of protocell internalization (see Supplementary Figure 13);
nanoparticles 100- to 150-nm in diameter were employed in the delivery of drugs, drug
cocktails, siRNA cocktails, protein toxins, and plasmid DNA. In order to maximize
targeting efficacy, the SLB was modified with various types of targeting ligands known
to have an affinity for HCC (see Supplementary Figure 14), and SP94 was selected for
use in delivery experiments. The nanoporous cores were soaked in a 10 mM solution of
cargo(s) for 1-12 hours prior to liposome fusion. The rate of intracellular cargo release
19

was optimized by incorporating various percentages of AEPTMS, an amine-containing
silane, into the sol used to form the nanoporous cores. Particles containing 30wt%
AEPTMS were used to deliver drugs and drug cocktails.
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Supplementary Figures and Legends:

Supplementary Figure 1. Saturation binding curves were constructed by exposing various concentrations
of fluorescently-labeled particles (unmodified and SP94-targeted protocells and liposomes) to a fixed
number of cells (HCC and control cells) and measuring the mean fluorescence intensity of each cell
population via flow cytometry. GraphPad Prism (GraphPad Software, Inc.; La Jolla, CA) was employed to
calculate dissociation constants (Kd) from binding curves. The above curve represents the Kd (~0.40 nM) of
DOPC protocells modified with 0.060 wt% SP94 (~30 peptides/particle) when exposed to Hep3B.
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Supplementary Figure 2. The Kd values of DOPC protocells modified with 0.500 wt% SP94 (~240
peptides/particle) for Hep3B and HepG2, the Kd of free SP94 for Hep3B, the Kd of unmodified DOPC
protocells (no peptide) for Hep3B, and the Kd values of SP94-targeted DOPC protocells (~240
peptides/particle) for human hepatocytes, endothelial cells (human umbilical vein endothelial cells, or
HUVECs), peripheral blood mononuclear cells (PBMCs), B-lymphocytes, and T-lymphocytes. SP94targeted DOPC protocells have a 104-fold higher affinity for HCC than for control cells, providing the
specificity necessary for efficacious delivery. All error bars represent 95% confidence intervals (1.96 σ) for
n = 5.
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Supplementary Figure 3. The Kd values of protocells can be precisely modulated from 0.10 nM to 100
nM by simply incorporating various amounts of fluid (DOPC) and non-fluid (DPPC) lipids into the SLB.
Kd values of DOPC protocells modified with 0.500 wt% SP94 (■) remain fairly constant as increasing
amounts of DPPC are incorporated into the SLB. Conversely, the Kd values of DOPC protocells modified
with 0.015 wt% SP94 (■) increase with increasing DPPC concentration. All error bars represent 95%
confidence intervals (1.96 σ) for n = 5.
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Supplementary Figure 4. The SP94 peptide directs protocells to lysosomes upon endocytosis by HCC, as
evidenced by the positive Pearson’s correlation (r) between SP94-targeted DOPC protocells (labeled with 5
wt% Texas Red DHPE) and lysosome-associated membrane protein-1 (labeled with Alexa Fluor 488).
Conversely, the Pearson’s correlation between protocells and Rab11 (labeled with Alexa Fluor 647) is ≈ 0,
which indicates that protocells are not localized within Rab11+ recycling endosomes. Differential
Interference Contrast (DIC) images were employed to define the boundaries of Hep3B cells, the nuclei of
which are labeled with DAPI, such that pixels outside of the cell boundaries could be disregarded when
calculating Pearson’s correlation coefficients (expressed as the mean value ± the standard deviation for n =
3 x 50 cells). Scale bars = 10 µm.
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Supplementary Figure 5. Zeta potential (ζ) values of DOPC liposomes (○), DOPC protocells (▼), and
nanoporous silica cores (●) when exposed to 1 mM KCl at pH 7 (a) or 1 mM KCl at pH 5 (b) for 2 hours.
Acidic conditions destabilize the SLB, as evidenced by the time-dependent decrease in the zeta potential of
DOPC protocells when exposed to the pH 5 buffer. Zeta potential values of DOPC liposomes and silica
nanoparticles at pH 7 and pH 5 correlate well with those that have been reported previously31. All error bars
represent 95% confidence intervals (1.96 σ) for n = 3.
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Supplementary Figure 6. Delivery of a siRNA cocktail to HCC via SP94-targeted protocells with
‘bimodal’ nanoporous cores. Bimodal silica nanoparticles (see Supplementary Methods) have large (10-30
nm), surface-accessible pores that can be rapidly loaded with siRNA, protein toxins, and other high
molecular weight cargos. (a) and (b) SP94-targeted protocells loaded with a siRNA cocktail that silences
expression of epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor-2
(VEGFR-2), and platelet-derived growth factor receptor-α (PDGFR-α) induce a dose- (a) and timedependent (b) decrease in target protein concentrations (determined via immunofluorescence) when
exposed to Hep3B. The concentrations of protocell-delivered siRNA necessary to silence 50% of EGFR
(●), VEGFR-2 (○), and PDGFR-α (▼) expression (IC50) within 24 hours are 6.68 nM, 4.18 nM, and 12.8
nM, respectively (a). Protocells loaded with the siRNA cocktail decrease EGFR (●), VEGFR-2 (○), and
PDGFR-α (▼) concentrations by >90% within 72 hours at a total siRNA concentration of 10 nM (b). (c)
SP94-targeted protocells loaded with 10 nM of the siRNA cocktail reduce EGFR, VEGFR-2, and PDGFRα expression in Hep3B (■) but not hepatocytes (■). (d) and (e) Confocal fluorescence microscopy was
utilized to confirm that SP94-targeted protocells are exclusively endocytosed by Hep3B (d) and, therefore,
do not induce a decrease in EGFR, VEGFR-2, or PDGFR-α concentrations when exposed to hepatocytes
(e). Upon endocytosis by Hep3B, SP94-targeted protocells with Alexa Fluor 647-labeled nanoporous cores
(white) are initially (1 hour) localized within endosomes but become dispersed in the cytosol within 4
hours; over the course of 72 hours, siRNA molecules are released from the nanoporous core and silence
nearly all EGFR, VEGFR-2, and PDGFR-α (green) expression. (f) – (h) SP94-targeted protocells loaded
with 10 nM of the siRNA cocktail kill 50% of Hep3B (●) within 36 hours without affecting the viability of
hepatocytes (○). Upon exposure to siRNA-loaded protocells, Hep3B cells become positive for Alexa Fluor
488-labeled annexin V (green) within 24 hours and double-positive for annexin V and propidium iodide
(red) within 48 hours (g). Hepatocytes remain double-negative for annexin V and propidium iodide when
exposed to SP94-targeted protocells loaded with siRNA for > 1 week (h). All error bars represent 95%
confidence intervals (1.96 σ) for n = 3. Nuclei are stained with DAPI in all fluorescence images. Scale bars
= 20 µm.
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Supplementary Figure 7. Delivery of diphtheria toxin A-chain to HCC using SP94-targeted protocells
with bimodal nanoporous cores. Diphtheria toxin is an exotoxin secreted by Corynebacterium diphtheriae
that is composed of two subunits (A and B) held together by a disulfide bond. The B-chain (39 kDa)
facilitates receptor-mediated endocytosis of the toxin, while the A-chain (24 kDa) inhibits protein synthesis
in eukaryotic host cells by using NAD as a substrate to catalyze the ADP-ribosylation of aminoacyltransferase II (EF-2)32. Active A-chain can be generated by exposing the native toxin to trypsin and a
reducing agent (e.g. dithiothreitol). (a) SP94-targeted protocells loaded with diphtheria toxin A-chain cause
a dose-dependent decrease in nascent protein synthesis when exposed to Hep3B for 24 hours. The IC50
value of toxin-loaded protocells is 92.0 nM. (b) and (c) Protocells that encapsulate 100 nM of diphtheria
toxin A-chain cause a 50% reduction in nascent protein synthesis within 24 hours and a 90% reduction
within 72 hours. Nascent protein synthesis was quantified using an Alexa Fluor 488-labeled derivative of
methionine (green), and protocell endocytosis by Hep3B was tracked using Alexa Fluor 647-labeled
nanoporous cores (white). (d) Diphtheria toxin A-chain delivered via SP94-targeted protocells induces
apoptosis in 50% of Hep3B cells (●) within ~18 hours at concentrations < 100 nM but has no cytotoxic
effect on hepatocytes (○). (e) Toxin-loaded protocells with Alexa Fluor 647-labeled cores (white) induce
caspase-8 activation (red) within 18 hours and capase-3 activation (green) within 36 hours when exposed to
Hep3B. (f) SP94-targeted protocells loaded with diphtheria toxin A-chain induce neither caspase-8 nor
caspase-3 activation when exposed to hepatocytes for > 1 week. All error bars represent 95% confidence
intervals (1.96 σ) for n = 3. Nuclei are stained with DAPI in all fluorescence images. Scale bars = 20 µm.
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Supplementary Figure 8. Release of doxorubicin (DOX) from protocells and liposomes under neutral and
acidic pH conditions. (a) The time-dependent release of DOX from DOPC protocells (●), DSPC liposomes
(○), DOPC liposomes (▼), and nanoporous cores (Δ) when exposed to growth medium (EMEM) with 10%
fetal bovine serum (FBS) at pH 7.4. Protocells exhibit long-term stability that is independent of the SLB
composition: given that their SLBs remain fully intact, DOPC-coated protocells release a negligible amount
of DOX when maintained in complete growth medium at 4°C for > 3 weeks. Conversely, DOPC liposomes
release nearly all of their encapsulated DOX within 72 hours. Thus, the fluid lipids that enable selective
targeting at low peptide densities cannot be used in liposomal drug formulations since pre-mature release of
encapsulated cargo results in non-specific toxicity to healthy cells; stable formulations of liposomal drugs
require the use of fully saturated, high Tm lipids and high concentrations of cholesterol, which act
cooperatively to increase the lipid packing density and limit diffusion of the drug across the bilayer 33. The
stability of ‘gold standard’ liposomal doxorubicin (e.g. DSPC with 30 mol% cholesterol, loaded using an
ammonium sulfate gradient approach) remains limited, however, as up to 30% of the drug is released
within 72 hours when stored in complete growth medium. (b) and (c) DOX-loaded protocells are stable
under neutral pH conditions and in the presence of serum proteins; they are, therefore, non-toxic to
hepatocytes (b). Pre-mature release of DOX from DSPC and DOPC liposomes results in intracellular
accumulation of DOX (red) within hepatocytes, as well as non-specific cytotoxicity (c). Non-viable cells
are labeled with a green fluorophore that can permeate the compromised membranes of apoptotic and
necrotic cells. (d) The time-dependent release of DOX from DOPC protocells (●), DSPC liposomes (○),
and DOPC liposomes (▼) when exposed to a pH 5 citric acid buffer. Acidic conditions destabilize the SLB
and promote release of DOX from the nanoporous core. (e) and (f) SP94-targeted protocells, the cores of
which are labeled with Alexa Fluor 647 (white), can deliver high enough concentrations of DOX to MDR
Hep3B to induce rapid cell death (e). SP94-targeted DSPC and DOPC liposomes deliver DOX to the
cytosol of MDR Hep3B but in insufficient concentrations to induce cytotoxicity (f). All error bars represent
95% confidence intervals (1.96 σ) for n = 3. Nuclei are stained with DAPI in all fluorescence images. Scale
bars = 20 µm.
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Supplementary Figure 9. The concentrations of free DOX, DOX-loaded protocells (PC-DOX), and
protocells that encapsulate a cocktail of DOX, 5-fluorouracil (5-FU), and cisplatin (PC-Cocktail) that are
necessary to kill 90% of Hep3B with induced MDR (■), parental Hep3B (■), or MDR Hep3B exposed to
cyclosporin A (CsA), which inhibits the Pgp efflux mechanism (■). Hep3B and HepG2 naturally express
low-to-moderate levels of P-glycoprotein (Pgp)34, the over-expression of which is a common cause of
MDR in various types of cancer cells. However, as Pgp expression is highly heterogeneous in HCC34, we
have induced MDR in parental Hep3B via chronic exposure to DOX. Nanocarriers that are internalized via
receptor-mediated endocytosis processes are typically able to circumvent the Pgp efflux mechanism and
can, therefore, induce cytotoxicity in MDR cells at lower drug concentrations. DOX delivered via SP94targeted protocells is capable of killing 90% of Hep3B with induced MDR (LC90) at a concentration that is
nearly 100-fold less than the LC90 value of free DOX (9.7 µM); protocells can decrease this value by
another order of magnitude due to their ability to simultaneously deliver DOX, as well as 5-FU and
cisplatin, neither of which are substrates for Pgp34,35. All error bars represent 95% confidence intervals
(1.96 σ) for n = 3.
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Supplementary Figure 10. Characterization of the two types of nanoporous silica particles employed as
protocell cores. The nanoporous silica particles that form the core of the protocell are prepared, as
previously described by us36,37, from a homogenous mixture of water-soluble silica precursor(s) and
amphipathic surfactant(s) using either aerosol-assisted evaporation-induced self-assembly (EISA) or by
solvent extraction-driven self-assembly within water-in-oil emulsion droplets (see Supplementary Methods
for more details). Solvent evaporation or extraction concentrates the aerosol or emulsion droplets in
surfactant(s), which directs the formation of periodic, ordered structures, around which silica assembles and
condenses. Surfactants are removed via thermal calcination, which results in porous nanoparticles with
well-defined, uniform pore sizes and topologies. Transmission electron microscopy (TEM, scale bars = 50
nm), dynamic light scattering (DLS), and nitrogen sorption indicate that particles formed via aerosolassisted EISA (‘monomodal’ particles) possess an average diameter of approximately 100-nm (after size
exclusion-based separation), a Brunauer−Emmer−Teller (BET) surface area in excess of 1200 m2/g, a pore
volume fraction of about 50%, and a unimodal pore diameter of 2.5-nm. Particles formed within emulsion
droplets (‘bimodal’ particles) have an average diameter of ~150-nm, a BET surface area of >600 m2/g, a
pore volume fraction of ~65%, and a bimodal pore morphology composed of large (10-30 nm), surfaceaccessible pores interconnected by 6-nm pores. Importantly, the liquid-vapor or liquid-liquid interfacial
tensions associated with aerosol or emulsion processing (respectively) enforce a spherical shape with
minimal surface roughness. Both types of particles have fully accessible three-dimensional pore networks,
as evidenced by TEM imaging and analysis of nitrogen sorption isotherms. The high pore volume, surface
area, and accessibility of the nanoporous silica cores imparts a high cargo capacity and enables rapid
loading of multiple types of therapeutic and diagnostic agents. Monomodal nanoporous cores have a high
capacity for low molecular weight chemotherapeutic agents, while bimodal cores possess the large, surfaceaccessible pores necessary for encapsulation of siRNA, protein toxins, and other high molecular weight
cargos. The rate of cargo release can be precisely controlled by the degree to which the silica core is
condensed. Incorporating various amounts of AEPTMS, an amine-containing silane, into the sol used to
form the nanoporous silica cores reduces the level of achievable condensation and promotes more rapid
dissolution of the cores under neutral pH, high ionic strength (i.e. cytosolic) conditions. Particles that
contain no AEPTMS dissolve over the course of 2 weeks, while particles that contain 30 mol% AEPTMS
dissolve within 24 hours (data not shown). Protocells can, therefore, be adapted for applications requiring
continuous or burst release profiles.
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Supplementary Figure 11. The non-specific affinity of protocells modified with 0.500 wt% of the SP94
peptide (~240 peptides/particle) for Hep3B and hepatocytes is a function of the charge and fluidity of lipids
employed in the SLB and the degree to which the SLB is modified with cholesterol or PEG. (a) and (b) The
affinity of SP94-targeted DOPC (■), DPPC (■), DOTAP (■), and DOPG (■) protocells for Hep3B (a) and
hepatocytes (b). Total binding is defined as the mean fluorescent intensity (MFI) of cells exposed to a
saturating concentration of SP94-targeted protocells (labeled with 1 wt% Texas Red DHPE), while nonspecific binding is defined as the MFI of cells exposed to a saturating concentration of unmodified
protocells (labeled with 1 wt% Texas Red DHPE). Specific binding is the difference between total binding
and non-specific binding. Lipids with a net positive (DOTAP) or negative charge (DOPG) increase the
non-specific binding of protocells to both HCC and hepatocytes. Employing zwitterionic lipids in the SLB
minimizes non-specific binding and maximizes specific binding; DPPC protocells have a slightly lower
non-specific affinity for Hep3B and hepatocytes than DOPC protocells. (c) The affinity of DOPC (■),
DOPC with 30 wt% cholesterol (■), DOPC with 5 wt% PEG-2000 (■), DPPC (■), DPPC with 30 wt%
cholesterol (■), and DPPC with 5 wt% PEG-2000 (■) protocells for Hep3B. Incorporating cholesterol or
PEG-2000 PE into the SLB further reduces the non-specific binding of DOPC and DPPC protocells to
HCC. All error bars represent 95% confidence intervals (1.96 σ) for n = 3.
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MitoSOX Red

Supplementary Figure 12. The non-specific toxicity of protocells is a function of the charge of lipids
employed in the SLB. (a) The degree to which ‘empty’ SP94-targeted protocells and liposomes induce
oxidative stress and subsequent cell death in Hep3B was determined using MitoSOX Red (■), a
mitochondrial superoxide indicator that fluoresces in the presence of superoxide anions, and propidium
iodide (■), respectively. Protocells and liposomes with bilayers composed of cationic (DOTAP) or anionic
(DOPG) lipids induce oxidative stress in up to 60% of Hep3B within 24 hours, while fewer than 10% of
Hep3B cells were positive for MitoSOX Red fluorescence upon exposure to protocells and liposomes with
bilayers composed of zwitterionic lipids (DOPC or DPPC). Silica nanoparticles alone had little effect on
Hep3B viability. Positively- and negatively-charged polystyrene nanoparticles (amine-PS and carboxyl-PS,
respectively) were employed as positive controls38, while Hep3B exposed to 10 mM of the antioxidant, Nacetylcysteine (NAC), was used as a negative control. All error bars represent 95% confidence intervals
(1.96 σ) for n = 3. (b) Confocal fluorescence microscopy was used to confirm that Hep3B cells become
positive for MitoSOX Red, as well as Alexa Fluor 488-labeled annexin V (green) and propidium iodide
(red) upon exposure to DOTAP protocells for 24 hours. Nuclei are stained with DAPI. Scale bars = 20 µm.
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Supplementary Figure 13.The overall diameter of the nanoporous core affects the achievable ligand
density, the specific affinity, and the average number of protocells endocytosed by a single HCC cell. (a)
As the diameter of the nanoporous core is increased from 4-nm to 200-nm, the SP94 density that is
achievable under saturating conditions (when 10 wt% DOPE is incorporated into the SLB) increases from 2
to >4000 peptides per protocell. (b) Since protocells with larger cores can display higher densities of the
SP94 peptide, they have a higher affinity (i.e. lower Kd values) for Hep3B. The dependence of Kd on the
diameter of the nanoporous core is less pronounced for DOPC (■) protocells than for DPPC (■) protocells;
since peptides can be recruited to the Hep3B surface when displayed on a fluid SLB, DOPC protocells can
retain high specific affinity at low peptide densities. (c) As the diameter of the nanoporous core increases,
fewer SP94-targeted DOPC (■) and DPPC (■) protocells are endocytosed by each Hep3B cell, which is,
presumably, due to the observation that membrane wrapping occurs most effectively for 30- to 60-nm
particles39. All error bars represent 95% confidence intervals (1.96 σ) for n = 3.
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Supplementary Figure 14. We modified the SLBs of protocells with various types of targeting ligands
that have an affinity for human hepatocellular carcinoma (HCC) in order to promote selective uptake and
multicomponent cargo delivery: the SP94 peptide, which was identified by Lo et al. to bind to HCC;
diferric transferrin (Tf), a glycoprotein involved in iron transport that binds to a receptor (transferrin
receptor, or TfR) upregulated by certain HCC cell lines40; a monoclonal antibody against epidermal growth
factor receptor (EGFR), which is overexpressed by many types of HCC41; and a monoclonal antibody
against an unknown HCC surface antigen (CHALV-1; Abcam; Cambridge, MA). (a) The maximum
number of ligands that can be conjugated to each protocell when DOPE is incorporated into the SLB at 5
wt% and when protocells are incubated with a saturating ligand concentration. Transferrin (~80 kDa, 8 x 10
nm42 ) and IgG (~150 kDa, 14.2 x 8.5 x 3.8 nm43 are 1000X larger than the SP94 peptide (~1500 Da); their
achievable densities are, therefore, 25- and 40-fold less (respectively) than that of SP94. (b) Kd values for
the free ligands, as well as for DOPC protocells modified with a high (5.0 wt%) or low (0.05 wt%) density
of each ligand when exposed to Hep3B (■) and hepatocytes (■). Only protocells modified with SP94 retain
their affinity for Hep3B at low ligand densities; protocells modified with a low density of Tf, anti-EGFR, or
CHALV-1 have Kd values similar to that of the monovalent ligand. Furthermore, SP94 has the lowest
inherent affinity for hepatocytes, which is likely due to the fact that TfR, EGFR, and the HCC surface
antigen targeted by CHALV-1 are not only expressed by HCC but by hepatocytes as well. Given that
DOPC protocells modified with a low density of SP94 (0.05 wt%) possess the highest achievable ligand
density, the highest affinity for HCC, and the lowest affinity for human hepatocytes, we chose to employ
SP94 as the targeting ligand in the majority of our studies. All error bars represent 95% confidence
intervals (1.96 σ) for n = 3.
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DOPC (T m = -20 C)

DOPE (T m = -16 C)

DPPC (T m = 41 C)

DPPE (T m = 63 C)

DSPC (T m = 55 C)

18:1 PEG-2000 PE

18:1 DOTAP (T m = -144 C)

16:0 PEG-2000 PE

DOPG (T m = -18 C)

18:1-12:0 NBD PC

16:0-12:0 NBD PC

Supplementary Figure 15. Structures of lipids employed in the SLB of protocells.
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CHAPTER 2

Multivalent Peptide Display on Virus-like Particles of MS2
Bacteriophage Facilitates Highly Specific Delivery of Cytotoxic Agents
to Cancer

It is widely accepted that the pharmacokinetic properties and therapeutic efficacy
of many monomeric anti-cancer drugs, as well as drug and gene delivery systems, can be
improved through their coupling to ligands that selectively target accessible cellular
receptors differentially or over-expressed by diseased cells or tissues, a concept that has
been clinically proven to enable dose optimization while mitigating undesirable side
effects (1). A plethora of ligands (antibodies and their fragments, peptides, growth
factors, glycoproteins, carbohydrates, vitamins, aptamers, etc.) have been utilized to
promote specific delivery of therapeutic and diagnostic agents (low molecular weight
drugs (2), therapeutic oligonucleotides (3), toxins (4), cytotoxic peptides (5),
radionuclides (4), cytokines (6), gold nanoparticles and nanoshells (7), quantum dots (8),
iron oxide and other superparamagnetic nanoparticles(9), gadolinium-based contrast
agents (10), etc.) to a wide variety of human cancers in vitro and in vivo. Therapeutic and
diagnostic agents can be directly conjugated to the targeting ligand (e.g. immunotoxins)
or loaded, via complexation or encapsulation, into a protein, polymer, or inorganic
particle that is modified with the targeting ligand. An astonishing number of targeted
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delivery systems have been developed since Moolten and Cooperband reported the first
tumor-specific immunotoxin in 1970 (11), including a multitude of nanoparticles
(liposomes, dendrimers, polymeric nanoparticles and micelles, carbon nanotubes,
inorganic nanoparticles, plant and animal viruses, bacteriophages, virus-like particles,
etc.) that rely on passive and active targeting mechanisms to direct their accumulation at
the tumor site and to promote their selective internalization by tumor cells (12).
Nanoparticles ≤ 150-200 nm in diameter are capable of escaping capture by the
reticuloendothelial system (RES) and become concentrated in the tumor interstitium due
to the enhanced permeability of disorganized tumor vasculature, as well as the decreased
draining efficacy of tumor lymphatics (i.e. the so-called enhanced permeability and
retention, or EPR, effect) (13). Nanoparticles can, furthermore, be surface-modified with
hydrophilic polymers, such as poly(ethylene glycol) (PEG), to reduce non-specific
interactions with serum proteins and endothelial cells, mitigate uptake by RES
macrophages, and decrease the magnitude of the humoral immune response (14).
Nanoparticles modified with tumor-specific ligands can home to tumor sites and, via
receptor-mediated endocytosis, deliver cytotoxic agents directly to the cytosol of tumor
cells, which increases the therapeutic index of many drugs and can circumvent or
overwhelm the P-glycoprotein (Pgp) efflux mechanism that contributes to multiple drug
resistance (MDR), a phenotype exhibited by numerous types of cancers (15). The
targeting efficacy of nanoparticle-based delivery systems depends on the inherent affinity
of the ligand for its cognate receptor, as well as the density of ligands displayed on the
nanoparticle surface. Monoclonal antibodies have been widely used to home
nanoparticles to various cell types due to their characteristically high specific affinity (Kd
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≤ 1 nM, typically) for the target receptor; their clinical utility can, however, be limited by
their size (~160 kDa), which precludes efficient tumor penetration, as well as their
immunogenicity and non-specific uptake by the RES, which can cause dose-limiting
toxicity (16). Combinatorial-based techniques, including phage display and SELEX
(systematic evolution of ligands by exponential enrichment), have

been utilized to

evolve high affinity peptides, antibody fragments (e.g. Fab and scFv fragments, single
VH domains, etc. (17)), and aptamers, which, due to their reduced size (0.50 – 25 kDa),
can more effectively penetrate tumors, are typically not recognized by the mononuclear
phagocytic system, are less likely to initiate immune responses, and can be displayed in
high densities on the surfaces of nanoparticles (16). Multivalent display of targeting
ligands dramatically increases the binding avidity of nanoparticles, often by three to five
orders of magnitude with respect to the monovalent ligand, which decreases the rate of
nanoparticle dissociation and can lead to more efficient internalization (18).
Targeted nanoparticles can be rapidly loaded with high concentrations of
therapeutic and diagnostic agents (relative to the drug concentrations that are achievable
via simple conjugation to targeting ligands), mitigate premature degradation of cargo, and
increase drug bioavailability. Many nanoparticles have, additionally, been engineered to
controllably release encapsulated cargo in the tumor microenvironment or upon
endocytosis (19, 20). PEGylated liposomes and dendrimers are extensively studied and
form the basis of several FDA-approved nanoparticle-based cancer therapeutics due to
their low inherent immunogenicity, as well as their biocompatibility, biodegradability,
and high degree of solubility in aqueous solvents (21, 22). Liposomes, dendrimers, and
polymeric nanoparticles have a cargo capacity that is limited by their interior volume,
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however, and cannot typically be adapted for use in applications requiring
multicomponent delivery. Conversely, a number of porous inorganic nanoparticles have
been developed that have a high capacity for disparate therapeutic and diagnostic agents
and can simultaneously deliver drugs, as well as molecules that increase the sensitivity of
fluorescence- and/or magnetic resonance-based imaging (23-27). The biodistribution and
non-specific toxicity of these multifunctional nanoparticles must be more thoroughly
characterized, however, before their in vivo utility is conclusively demonstrated.
Plant and animal viruses, bacteriophages, and virus-like particles have received
considerable attention in the past decade for their utility in a wide variety of applications
that span multiple scientific disciplines, including peptide-directed formation of inorganic
nanomaterials and nanoparticles (28-30), vaccine development (31-33), and targeted
delivery of drugs and genes to a wide variety of cell types (34, 35). Viruses and
bacteriophages possess numerous characteristics that make them of interest as targeted
nanocarriers, including their inherent ability to encapsulate DNA and RNA, as well as
their high degree of monodispersity and their ability to be modified with high densities of
diverse targeting ligands. Furthermore, filamentous (M13, fd, and f1) and lytic (T7, T4,
and λ) bacteriophages have been used as display platforms for complex libraries of
randomized peptide or scFv sequences. Phage display is a remarkably powerful,
combinatorial-based technique that enables evolution of ligands with a high specific
affinity for target cells or cellular receptors without a priori knowledge of the amino acid
sequence (16, 17, 36, 37). Filamentous phage M13, the basis of most commerciallyavailable display systems, has been extensively utilized to identify targeting ligands that
bind to recombinant proteins differentially or over-expressed by cancer cells, as well as
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entire cancer cell lines or freshly-excised tumor cells (36, 38). Phage display has,
additionally, been used to recover ligands with an affinity for tumor vasculature,
extracellular matrix components, and necrotic areas using in vivo and ex vivo techniques
(39, 40). Peptides and antibody fragments identified by phage display are typically
conjugated to liposomes or polymeric nanocarriers, which can reduce the affinity of the
ligand for its target receptor. Attempts have, therefore, been made to utilize recombinant
M13 particles for targeted delivery (34, 41, 42). Filamentous phages, however,
selectively package their genome via complex, cooperative interactions between DNA
and coat proteins, making it difficult to encapsidate non-genomic materials (43); drugs
and other cargo must, therefore, be conjugated to the external surface of their capsids. To
circumvent this limitation, researchers have reconstituted coat protein-random peptide
fusions in the bilayers of drug-loaded liposomes (44), fused drug-loaded liposomes to
M13 bearing tumor-specific peptides (45), and utilized other types of viruses,
bacteriophages, and virus-like particles with a cargo capacity.
Adenovirus has been extensively adapted for use in targeted gene therapy due to
its natural ability to transfect host cells with double-stranded DNA, including plasmids
that encode reporter proteins. Adenoviral vectors are typically PEGylated to suppress the
innate immune response and mitigate coxsackievirus-adenovirus receptor (CAR)mediated endocytosis and modified with tumor-specific ligands to promote selective
transfection of cancer cells with the gene of interest (46, 47). Polyomavirus (48, 49),
lambda phage (50), and bacteriophage phi-29 (51) have been engineered in a similar
manner to deliver reporter genes and siRNA, while the natural affinity of canine
parvovirus for transferrin receptor (TfR) has been utilized to promote cell-specific uptake
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of parvovirus-like particles (52). Icosahedral plant viruses, including Cowpea chlorotic
mottle virus (CCMV) (53), Cowpea mosaic virus (CPMV) (54, 55), and Hibiscus
chlorotic ringspot virus (HCRSV) (56), have been emptied of their genomic RNA, loaded
with various types of exogenous materials, including gold nanoparticles and
chemotherapeutic drugs, and targeted to cancer cells via modification with folic acid or
peptides that bind to receptors typically over-expressed by cancer (e.g. vascular
endothelial growth factor receptor, or VEGFR).
More recently, virus-like particles (VLPs) of MS2 bacteriophage have been
engineered for use in targeted delivery and address several limitations associated with
nanocarriers derived from filamentous phages and plant viruses. MS2 VLPs selfassemble from 180 copies of a single coat protein (13.7 kDa) into a perfectly
monodisperse, 27.5-nm capsid with icosahedral symmetry (T = 3). The periodicity of the
capsid, the presence of surface-accessible amino acid residues with reactive moieties (e.g.
lysine and glutamic acid), and the tolerance of a genetically-fused coat protein dimer (the
so-called single-chain dimer (33)) for ≥ 90% of peptide insertions enables dense,
repetitive display of peptides and antibody fragments via chemical conjugation or genetic
insertion and aptamers, vitamins, glycoproteins, etc. via chemical conjugation. Stockley,
et al. used heterobifunctional crosslinkers to modify MS2 VLPs with transferrin for
targeted delivery of ricin A-chain or antisense oligonucleotides to TfR+ cells (57, 58),
while Francis, et al. employed lysine residues, as well as an unnatural amino acid (paminophenylalanine, inserted at position 19 of MS2 coat protein) to link peptides,
aptamers, and PEG to the exterior surface of MS2 VLPs and promoted stable
encapsulation of chemotherapeutic drugs, Gd-based contrast agents, and fluorescent
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molecules via conjugation of cargo to functionalized amino acids present on the interior
capsid surface (59-63). Another attractive feature of MS2 VLPs is that their interior
volume can be rapidly loaded with a variety of non-genomic materials using several
approaches. Hollow capsids can be produced from native bacteriophages via hydrolysis
of the genome (64) or by expression of coat protein from a plasmid in transformed
Escherichia coli (63, 65, 66). The presence of 32 pores, each of which is ~1.8-nm in
diameter, in the MS2 capsid enables diffusion of small molecules into the interior
volume, a technique that Stockley and Francis have employed to encapsidate antisense
oligonucleotides, fluorescent molecules, chemotherapeutic drugs, and Gd-based contrast
agents (58, 60, 61, 63). Furthermore, MS2 coat protein naturally self-assembles in the
presence of RNA (see below for more details), enabling cargos modified with RNA to be
selectively encapsidated within the interior volume, a technique Stockley has employed
to load MS2 VLPs with ricin A-chain. Additionally, the abundance of lysine residues on
the interior capsid surface suggests that negatively-charged cargos of the appropriate size
can be encapsidated within MS2 VLPs via non-specific electrostatic interactions (43).
MS2 VLPs are biocompatible, biodegradable, stable under a variety of temperature, pH,
and solvent conditions, and are easily synthesized and purified in large quantities using
safe, cost-effective procedures. Their structural simplicity enables their synthesis in vivo
using saturated bacterial cultures, as well as entirely in vitro using cell-free protein
synthesis systems (67). Finally, Peabody et al. are developing MS2 VLPs as a platform
for random peptide (33) and scFv (unpublished results) display. MS2 VLPs are the only
particles, to date, that possess both the random peptide display capabilities of filamentous
phage and the cargo capacity of the hollow capsid.
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Here we report the simultaneous delivery of multiple types of chemically
disparate therapeutic and diagnostic agents to human hepatocellular carcinoma (HCC)
using MS2 VLPs modified with high densities of targeting peptides that have an affinity
for HCC (Fig. 1A). Peptides conjugated to surface lysine residues present in the VLP
capsid or genetically inserted in a surface loop of coat protein are displayed on the VLP
surface in dense, repetitive arrays (90-240 copies per VLP) (33). Multivalent display of
peptides with an affinity for HCC promotes highly specific surface binding and
internalization of MS2 VLPs by HCC (Fig. 1B) but not by normal hepatocytes (Fig. 1C).
MS2 VLPs, furthermore, naturally self-assemble in the presence of RNA, enabling
specific encapsidation of therapeutic RNAs, as well as any molecule or nanoparticle (≤
16-nm in diameter) that can be surface-modified with RNA (Fig. 1D). Specific
internalization of targeted VLPs combined with the cargo capacity of the hollow capsid
enable selective delivery of a variety of cytotoxic and imaging agents to HCC (Fig. 1E)
without affecting the viability of hepatocytes and other control cells in vitro.

Results and Discussion
Modification of Cargo with RNA Promotes Specific Encapsidation of Disparate
Therapeutic and Diagnostic Agents within MS2 VLPs. MS2 VLPs can be rapidly
loaded with a variety of therapeutic and diagnostic agents and surface modified with
ligands, including peptides, aptamers, and transferrin, that promote specific uptake by
cancer cells. Several approaches for loading MS2 VLPs with various types of cargos have
been reported that either utilize the 1.8-nm pores present in the MS2 capsid to passively
diffuse small molecules into the interior volume or employ nucleic acids to drive capsid
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assembly (58, 60, 61, 63). MS2 coat protein, when expressed from a plasmid in
transformed E. coli, can spontaneously form hollow capsids in the absence of RNA (65,
66); hollow capsids can also be formed by exposing MS2 bacteriophage to basic
conditions to promote hydrolysis of the genome (64). Soaking hollow capsids in a
solution containing the cargo of interest promotes diffusion of the cargo into the interior
volume of the capsid; negatively-charged cargos (e.g. RNA and antisense
oligonucleotides) are retained via electrostatic interactions with coat protein, while small
molecule drugs or fluorophores pre-modified with reactive moieties can form covalent
bonds with functionalized amino acids present on the interior capsid surface (59). MS2
coat protein, typically harvested via acetic acid or urea-driven disassembly of native MS2
bacteriophage (57), can also spontaneously assemble into complete capsids upon addition
of nucleic acids. The efficacy and rate of capsid assembly are maximized in the presence
of the MS2 translational operator, a 19-nucleotide RNA stem-loop that, via its interaction
with coat protein, mediates exclusive encapsidation of the MS2 genome during
bacteriophage replication (57, 65, 68). The MS2 operator, or pac site, can promote
efficient encapsidation of non-genomic materials within the interior volume of MS2
VLPs upon conjugation of the pac site to the cargo of interest (57, 58). MS2 VLPs will
also, however, encapsidate RNA hairpins with sequences that differ from that of the
native operator (68), as well as heterologous nucleic acids, including single- and doublestranded RNA and DNA ≤ 3 kbp in length.
We have encapsidated various types of therapeutic (drugs, siRNA, and protein
toxins) and imaging (quantum dots) agents within the interior volume of MS2 VLPs (Fig.
1A) by exploiting their natural ability to assemble in the presence of both heterologous
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nucleic acids and cargos modified with the pac site. We used thiol-cleavable,
heterobifunctional

crosslinkers

(e.g.

succinimidyl

6-(3-[2-pyridyldithio]-

propionamido)hexanoate, or LC-SPDP, which is reactive toward sulfhydryls and primary
amines) to conjugate the pac site, modified with a 3’ sulfhydryl moiety and (U)3-9 spacer,
to a CdSe/ZnS core-shell quantum dot, passivated with amine-terminated PEG (Fig. 1D),
as well as the chemotherapeutic drugs, doxorubicin and cisplatin, both of which contain
primary amine groups; the use of crosslinkers that are cleavable via reduction is critical to
liberate cytotoxic agents in the cytosol of target cancer cells. We employed a similar
strategy to conjugate the pac site, modified with a 3’ amine moiety, to the A-chain of
ricin toxin, which contains a free cysteine residue. To encapsidate a cocktail of
doxorubicin, cisplatin, and 5-fluorouracil, we incorporated three internal 5-fluorouridine
moieties into the pac site sequence, which was further modified with a 5’ thiol group to
enable conjugation to doxorubicin and cisplatin. To harvest coat protein for the
reassembly reaction, we exposed native MS2 bacteriophage to glacial acetic acid, which
promotes precipitation of the RNA genome and maturase, as well as disassembly of the
capsid into coat protein monomers, and dialyzed resulting monomers against 20 mM
acetic acid, which favors the formation of coat protein dimers. Upon addition of buffered
siRNA or pac site-modified cargo, ninety dimers spontaneously reassemble around the
cargo to form a complete, 27.5-nm capsid (Fig. 1D). Using this technique, the reassembly
reaction yield varied from ~40% to ~90%, depending on the type of cargo; nearly 100%
of fully-assembled VLPs contained encapsidated cargo (results not shown). Loading
efficiencies for each type of cargo are described below.
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To demonstrate that MS2 VLPs are capable of simultaneously encapsidating and
delivering a variety of therapeutic and diagnostic agents to HCC, we first incubated an
excess of coat protein dimers with a mixture of pac site-modified quantum dots and
doxorubicin, as well as fluorescently-labeled siRNA and ricin A-chain modified with a
fluorescently-labeled derivative of the pac site. We then purified fully assembled capsids
via size-exclusion chromatography, chemically conjugated a targeting peptide that
promotes selective uptake of VLPs by HCC to the capsid surface, and fluorescentlylabeled

the

capsid

using

Alexa

Fluor®

555

hydrazide

and

1-ethyl-3-[3-

dimethylaminopropyl]carbodiimide hydrochloride (EDC). Upon exposing the HCC cell
line, Hep3B, to targeted VLPs loaded with the multicomponent cargo mixture, we
employed hyperspectral confocal fluorescence microscopy to individually track the four
types of cargo, as well as the capsid, within the cytosol of a Hep3B cell. As is clearly
demonstrated in Fig. 1E, targeted VLPs can deliver a high payload of chemically
disparate therapeutic and imaging agents to cancer cells in vitro.
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Figure 1. Targeted delivery of disparate therapeutic and diagnostic agents to human hepatocellular
carcinoma (HCC) via multivalent display of the SP94 targeting peptide on virus-like particles (VLPs) of
MS2 bacteriophage. (A) Various types of cargo can be specifically encapsidated within the interior volume
of MS2 VLPs (via the scheme depicted in part D), including nanoparticles, siRNA, protein toxins (e.g. ricin
A-chain), and chemotherapeutic agents (e.g. doxorubicin). The surface of the protein capsid (yellow) can,
furthermore, be modified in precise locations with functional peptides (red) via chemical conjugation
(using a heterobifunctional crosslinker with a PEG spacer arm) in order to target VLPs to a diseased cell or
tissue or to promote endosomal escape once VLPs are internalized within the target cell. (B)-(C) VLPs
(red) modified with the SP94 targeting peptide are internalized within HCC (B) but not hepatocytes (C),
demonstrating that SP94 confers the specificity necessary for efficacious targeted delivery. VLPs are
labeled with Alexa Fluor® 555 and cells are labeled with a blue fluorescent nuclear stain (Hoechst 33342)
and CellTrackerTM Green CMDFA. Scale bars = 10 µm. (D) Various types of cargo can be encapsidated
within MS2 VLPs via modification with the pac site, a 19-nucleotide RNA hairpin loop present in the
bacteriophage genome that is thought to initiate capsid assembly. Primary amine-functionalized cargos are
conjugated to the pac site, modified with a 3’ sulfhydryl moiety, via a heterobifunctional crosslinker (LCSPDP). Ninety coat protein dimers then self-assemble around siRNA or RNA-modified cargo to form the
27.5-nm capsid. The yield of fully-assembled capsids is depicted in the TEM image of VLPs, each of
which encapsidates ~90 siRNAs (scale bar = 50 nm). Arrows point to the locations of surface-accessible
lysine residues, which are utilized to conjugate targeting and fusogenic peptides to the capsid surface. (E)
Hyperspectral confocal fluorescence imaging can be employed to demonstrate that targeted VLPs are
capable of simultaneously delivering a cocktail of ricin A-chain (modified with an Alexa Fluor® 488labeled derivative of the pac site), pac site-modified Qdot® 585 ITKTM amino(PEG) quantum dots, pac sitemodified doxorubicin (naturally emits at 560 nm and 592 nm when dissolved in water 1, and Alexa Fluor®
647-labeled siRNA specifically to HCC Hep3B (labeled with Hoechst 33342 and CellTrackerTM Violet
BMQC). Scale bars = 20 µm.
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Multivalent Display of Targeting Peptides Enhances the Specific Affinity of MS2
VLPs for HCC. MS2 VLPs can be modified with high densities (≥ 30 ligands per VLP)
of peptides, aptamers, and other low molecular weight (≤ 25 kDa) targeting ligands
through chemical conjugation to surface-accessible amino acids with reactive moieties
(e.g. lysine, glutamic acid, etc.) (59, 62, 63). Multivalent display of targeting ligands on a
nanoparticle surface enhances the affinity of the monovalent ligand for the target cell or
cellular receptor through collective binding effects that promote high avidity interactions
between nanoparticles and the target cell surface (18, 63, 69, 70). We have employed
peptide, glycoprotein, and antibody-based ligands that are known to bind to HCC to
determine how ligand size, inherent affinity, and density influence specific surface
binding of MS2 VLPs. The SP94 (H2N-SFSIIHTPILPL-COOH) peptide, which has an
affinity for unknown HCC surface antigen(s), was isolated from a filamentous phagedisplayed dodecapeptide library via affinity selection against the HCC cell line, Mahlavu
(71). Similarly, the GE11 peptide, which has an affinity for human epidermal growth
factor receptor (hEGFR), and the HBsAgP peptide, which has an affinity for Hepatitis B
surface antigen (HBsAg), were isolated from dodecapeptide and octapeptide libraries,
respectively, by biopanning immobilized hEGFR (recombinant) or HBsAg (purified from
the serum of HBV-infected patients) (72, 73). EGFR is over-expressed by many types of
cancer, including HCC (74), while HBsAg can be expressed and secreted by HCC
derived from hepatocytes chronically infected with HBV (75). In addition to peptide
ligands, we employed diferric transferrin (Tf), a glycoprotein involved in iron transport
that binds to a receptor (TfR) upregulated by several HCC cell lines (76) and a
monoclonal antibody (CHALV-1) against an unknown HCC surface antigen. All peptides
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were synthesized with C-terminal cysteine residues (separated from the affinity selected
sequence via a (Gly)2 spacer) and conjugated to surface lysine residues present in the
MS2

capsid

using

the

heterobifunctional

crosslinker,

succinimidyl-[(N-

maleimidopropionamido)-tetracosaethyleneglycol] ester (SM(PEG)24, which is reactive
toward amine and sulfhydryl groups and contains a PEG spacer arm 9.5-nm in length. Tf
and CHALV-1 were first activated with N-succinimidyl-S-acetylthioacetate (SATA),
which adds protected sulfhydryls to primary amines, and then conjugated to MS2 VLPs
using SM(PEG)24. Crosslinkers with PEG spacers were used to reduce any steric
hindrance that might interfere with ligand binding and to enable PEGylation of the MS2
surface, which reduces non-specific interactions and prevents recognition of MS2 VLPs
by anti-MS2 antibodies (see below for more details).
We found that, under saturating conditions, each MS2 VLP can be modified with
an average of 246 (± 9) peptides and that the peptide density can be reduced via reaction
stoichiometry, as well as reaction time and temperature. Since glycoproteins and
antibodies are substantially larger than peptide ligands (~40X and 80X, respectively), the
density of Tf and CHALV-1 that is achievable under saturating conditions is more than
an order of magnitude lower (Fig. S1A) than that of SP94, EC11, and HBsAgP, which
limits the avidity of Tf- and CHALV-1-modified VLPs. We quantified the avidity of
targeted MS2 VLPs for various HCC cell lines, as well as non-transformed hepatocytes,
by measuring dissociation constants (Kd), which are a measure of specific surface binding
and inversely proportional to avidity (i.e. low dissociation constants are indicative of high
affinity or avidity). Although SP94, EC11, and HBsAgP have a lower inherent affinity
for Hep3B than Tf or CHALV-1, MS2 VLPs modified with a high density (~240 peptides
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per VLP) of any one targeting peptide have Kd values that are more than an order of
magnitude less than the Kd values of Tf- and CHALV-1-modified VLPs (Fig. S1B),
which highlights the importance of multivalency in maximizing avidity. Although MS2
VLPs modified with SP94, EC11, HBsAgP, Tf, or CHALV-1 have a high avidity for
Hep3B, the degree to which they bind to other HCC cell lines, including HepG2 and
PLC/PRF/5, strongly depends on the surface density of target receptor(s). Ligands that
bind to unknown HCC surface antigen(s), such as SP94 and CHALV-1, have a high
specific affinity for HCC, as evidenced by the 103-fold difference between their Kd values
for Hep3B, HepG2, or PLC/PRF/5 and their Kd values for hepatocytes (Fig. S1C).
Conversely, VLPs that display the EC11 peptide or Tf bind to HCC only 100-fold more
effectively than they bind to hepatocytes due to the varying degree of EGFR (77) and
TfR (78) over-expression by HCC, while VLPs that display HBsAgP are highly specific
for the HCC cell lines that are positive for HBsAg expression (Hep3B and PCL/PRF/5)
but not for HBsAg- cells lines (HepG2). Given that SP94-targeted MS2 VLPs possess the
highest specific affinity for HCC and exhibit the lowest degree of non-specific binding to
hepatocytes, we chose to employ SP94 as the targeting ligand in all subsequent
experiments.
MS2 VLPs bearing 240 copies of the SP94 peptide have sub-nanomolar avidity for
Hep3B, HepG2, and PLC/PRF/5 (Fig. 2A), the magnitude of which is retained when
HCC cells are co-cultured with hepatocytes (Fig. S2). SP94-modified VLPs, furthermore,
have a 500-fold higher affinity for Hep3B than monovalent SP94, a 2000-fold higher
affinity for Hep3B than VLPs bearing 240 copies of an irrelevant peptide (H2NFPWFPLPSPYGNGGC-COOH (71)), and an 85,000-fold higher affinity for Hep3B than
52

unmodified VLPs. Importantly, VLPs displaying the SP94 peptide have between a 10,000
and 20,000-fold higher affinity for Hep3B than for human hepatocytes, endothelial cells
(HUVECs), and immune cells (peripheral blood mononuclear cells (PBMCs), Blymphocytes, and T-lymphocytes), providing the specificity necessary for efficacious
targeted delivery (Fig. 2A). We have utilized atomic force microscopy (AFM) to confirm
that SP94-targeted VLPs specifically bind to HCC by employing MS2 VLPs, covalently
coupled to a gold-coated AFM tip and modified with high SP94 densities, to probe the
surfaces of Hep3B cells before and after addition of exogenous SP94. Fig. 2D shows a
contour map, superimposed on a fluorescence image of a Hep3B cell, that diagrams
adhesion events that occurred between SP94-modified VLPs and unknown antigen(s) on
the Hep3B surface. The pattern of adhesion events suggests that target receptor(s) are
pre-clustered on the Hep3B surface prior to binding of SP94-targeted VLPs. The
histogram in Fig. 2E plots observed rupture events, the magnitude of which was largely
between 20 and 70 pN. Upon addition of exogenous SP94, the incidence of ≥ 40 pN
adhesions decreases dramatically, which indicates that the rupture force for specific
surface binding of SP94 to HCC is in the range of 40-70 pN (comparable to other
biological interactions (79-81)).
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Figure 2. MS2 VLPs modified with the SP94 peptide have a high specific affinity for human HCC, the
magnitude of which is dependent on the type(s) and density of targeting peptides. (A) MS2 VLPs modified
with 240 copies of the SP94 peptide have a high specific affinity for the HCC lines, Hep3B, PLC/PRF/5,
and HepG2, as evidenced by their low Kd values (≤ 1 nM), which are 104-fold lower than the Kd of targeted
VLPs for hepatocytes, endothelial cells (HUVECs), and immune cells (PBMCs and B- and Tlymphocytes), 500-fold lower than the Kd of free SP94 for Hep3B, 2000-fold lower than the Kd of MS2
VLPs modified with a control peptide (with no known affinity for HCC) for Hep3B, and > 104-fold lower
than the Kd of unmodified VLPs (no peptide) for Hep3B. The dissociation constant (Kd) is a measure of
specific surface binding and is inversely related to affinity (i.e. VLPs with a low Kd value have a high
specific affinity for the target cell). (B) The affinity of targeted VLPs for Hep3B is a function of the peptide
density and type. SP94 (■) and SP88 (■) targeting peptides are displayed in precise, yet fixed locations on
the VLP surface; therefore, the affinity of targeted VLPs for Hep3B decreases (i.e. Kd increases) with
decreasing peptide density since multivalent effects are less pronounced at lower peptide densities. SP88
has a lower inherent affinity for Hep3B than SP94; therefore, VLPs modified with SP88 have a lower
affinity for Hep3B than VLPs modified with SP94 at all peptide densities. * indicates that the indicated
values are NOT significantly different (using ANOVA, p ~ 0.47 for n = 5). (C) VLPs modified with a
combination of SP94 and SP88 retain their overall affinity for Hep3B (Kd ~1 nM) when both peptides are
present in an average density of 60 peptides per VLP (■). VLPs modified with ~3 copies each of the SP94
and SP88 peptides have a slightly lower specific affinity for Hep3B (■); reducing the peptide density might
reduce the immunogenicity of targeted VLPs, however. (D, left) A fluorescence image of a Hep3B cell, the
cytosol of which is stained with CellTrackerTM Red CMTPX and the nucleus of which is stained with
Hoechst 33342 (blue). Scale bar = 20 µm. (D, right) A contour map demonstrating the pattern and strength
of adhesion events between the indicated region of the Hep3B surface and an Atomic Force Microscope
(AFM) tip modified with VLPs to which the SP94 peptide is conjugated in high density (~240 peptides per
VLP). The pattern of adhesion events with a magnitude in the 40-70 pN range tend to be clustered on the
Hep3B surface when the experiment is performed at room temperature. Contours represent 60 pN and 120
pN total rupture force. (E) A histogram plotting the number of adhesion events at various rupture forces
demonstrates that an AFM tip modified with VLPs that display the SP94 peptide in high density binds to
the surface of a Hep3B cell with high affinity (■), which can be competitively inhibited via the addition of
exogenous SP94 (■); the resulting histogram has minimal adhesion events ≥ 40 pN, indicating that specific
rupture forces are in the 40-70 pN range. All error bars represent 95% confidence intervals (1.96 σ) for n =
5.
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The avidity of MS2 for HCC is strongly dependent on the density of targeting
peptides displayed on the VLP surface, as well as (to a lesser extent) the inherent affinity
of the targeting peptide for HCC. As demonstrated in Fig. 2B, the affinity of MS2 VLPs
for Hep3B remains essentially constant when at least one-third of coat protein monomers
are modified with the SP94 peptide (~60 peptides per VLP). As SP94 density decreases,
however, the affinity of MS2 VLPs for Hep3B decreases (i.e. Kd values increase), since
the multivalent interactions that promote high avidity binding are less pronounced at low
ligand densities. Furthermore, the Kd values of MS2 VLPs modified with the SP88
peptide (H2N-ELMNPLLPFIQP-COOH; identified to have an affinity for HCC in the
same manner as SP94 (71)) are higher at all peptide densities than the Kd values of SP94targeted VLPs since SP88 has a lower inherent affinity for Hep3B (489.2 ± 31.4 nM for
SP88 versus 211.1 ± 12.2 nM for SP94).
Multivalent display of targeting peptides on the surfaces of MS2 VLPs promotes a
high specific affinity for the cancer cell of interest but will likely initiate an antibody
response against the peptide as well. Possible strategies for suppressing the humoral
immune response against targeted VLPs include reducing the density of surfacedisplayed ligands or masking the capsid with PEG. Phage display enables identification
of numerous different peptide sequences, all of which have a high affinity for the target
cell. Multiple targeting peptides can, therefore, be conjugated to MS2 VLPs in order to
decrease the valency of each peptide, which should mitigate the immunogenicity of the
targeted VLP without reducing its overall avidity for the target cell. Fig. 2C demonstrates
that MS2 VLPs modified with 30 copies each of SP94 and SP88 retain their subnanomolar affinity for Hep3B. Even when VLPs are modified with only three copies of
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each peptide, their Kd for Hep3B remains sufficiently low (~ 20 nM) to enable selective
targeting of HCC. PEGylation of MS2 VLPs should minimize proteolytic degradation of
the capsid, reduce the humoral immune response against coat protein, and mitigate nonspecific interactions with non-target cells, all of which will increase the circulation halflife and enhance bioavailability of encapsidated cargo (59). We have demonstrated that
coupling methyl-(PEG)24-amine (~1000 Da with a spacer arm 8.6-nm in length) to the
MS2 capsid using EDC results in > 80% modification and reduces recognition of MS2
VLPs by anti-MS2 monoclonal antibodies (results not shown). Masking a nanoparticle’s
surface with PEG, however, typically reduces its specific affinity for the target cancer
cell by interfering with ligand binding (82). We have tested the degree to which
PEGylated MS2 VLPs, surface-modified with SP94 using an extended-length crosslinker
(SM(PEG)24), bind to Hep3B and hepatocytes and have found that PEG-1000 does not
substantially affect (p ~ 0.055 for n = 5 using the unpaired t test) the specific affinity of
targeted VLPs for HCC (Fig. S1D).
Upon binding, SP94-targeted VLPs are rapidly endocytosed (t½ = 6 minutes) by
HCC (Fig. 1B) but show minimal surface binding and absolutely no internalization by
hepatocytes (Fig. 1C). We have confirmed that the SP94 peptide directs VLPs to
lysosomes upon endocytosis (Fig. S3) and have, therefore, further modified the capsid
with

a

histidine-rich

fusogenic

peptide

(Fig.

1A;

H5WYG,

H2N-

GLFHAIAHFIHGGWHGLIHGWYG-COOH (20)) that, upon protonation (pKa = 6.0),
induces osmotic swelling and membrane destabilization of endosomes without affecting
the integrity of the plasma membrane. MS2 VLPs that co-display the SP94 and H5WYG
peptides become dispersed in the cytosol of HCC cells within 1-4 hours of endocytosis
56

(Fig. S4), which indicates that degradation of sensitive or macromolecular cargo in the
lytic lysosomal environment can be avoided.

Delivery of a Chemotherapeutic Cocktail to HCC via SP94-Targeted VLPs Induces
Selective Cytotoxicity of HCC. To demonstrate the utility of MS2 VLPs in targeted
delivery of cytotoxic agents to cancer, we encapsidated the chemotherapeutic drug,
doxorubicin (trade name, Adriamycin®) by conjugating it to the 3’ end of the pac site.
Doxorubicin (DOX) is broad-spectrum anthracycline antibiotic that was isolated from
Streptomyces peucetius in the early 1960’s and approved by the FDA for treating human
cancers in 1974. DOX inhibits DNA and RNA synthesis equally by intercalating doublestranded DNA and binding to topoisomerase II; DOX can, additionally, interact with
anionic phospholipids present in cellular membranes to disrupt their macromolecular
architectures (83). Enzymatic reduction of doxorubicin generates highly reactive free
radicals, which are the leading cause of dose-limiting cardiotoxicity and painful palmarplantar erythrodysesthesia (i.e. hand- foot syndrome). PEGylated liposomal doxorubicin
(trade name, Doxil®), which received FDA approval in 2005, becomes concentrated in
solid tumors via the EPR effect and, therefore, mitigates many adverse side effects
associated with monomeric doxorubicin; active targeting of nanoparticle-encapsulated
doxorubicin should further reduce non-specific toxicity and enable dose optimization.
MS2 VLPs each encapsidate 103 ± 9 molecules of doxorubicin, and, upon
modification of the capsid with SP94, drug-loaded VLPs can induce selective apoptosis
of Hep3B at nanomolar concentrations. Hep3B naturally expresses moderate levels of Pglycoprotein (Pgp), an efflux pump that is typically upregulated by cells during
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acquisition of a MDR phenotype, which results in reduced intracellular accumulation of
certain drugs, including anthracyclines (84). The concentration of doxorubicin necessary
to kill 90% of MDR Hep3B (LC90) in a population containing 1 x 106 cells/mL is 285.6 ±
8.2 nM, a value that can be reduced via inhibition of Pgp using cyclosporin A (CsA) (84)
or addition of cisplatin and 5-fluorouracil (5-FU), neither of which are substrates for Pgp
(85, 86) (Fig. 3A). Targeted nanocarriers that are internalized via receptor-mediated
endocytosis are typically able to circumvent Pgp efflux mechanisms and can, therefore,
kill MDR cancer cells at lower drug concentrations. DOX delivered via SP94-targeted
MS2 VLPs is capable of killing 90% of MDR Hep3B at a concentration that is more than
10-fold less that LC90 value of free DOX. More impressively, MS2 VLPs loaded with
DOX (45 ± 3 per VLP), cisplatin (49 ± 5 per VLP), and 5-FU (234 ± 16 per VLP), a
chemotherapeutic drug cocktail known to be particularly effective against HCC (86) can
kill 90% of MDR Hep3B at concentrations < 1 nM (Fig. 3A) without substantially
affecting the viability of hepatocytes (Fig. 3B). VLPs of Qβ, a 28.5-nm icosahedral
bacteriophage that is more stable than MS2 due to extensive disulfide crosslinking of its
capsid, have a similar cytotoxic effect on MDR Hep3B but mitigate long-term hepatocyte
toxicity (Fig. 3B)
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Figure 3. VLPs of MS2 and structurally related bacteriophages (e.g. Qβ) are capable of delivering a
sufficient concentration of chemotherapeutic agents to induce cytotoxicity in Hep3B but not hepatocytes.
(A) Doxorubicin (DOX) can be encapsulated within MS2 and Qβ VLPs via conjugation to the pac site, and
a sufficiently high concentration can be delivered, via SP94-targeted VLPs, to DOX-resistant Hep3B to
induce cytotoxicity at IC90 values of 10-15 nM, a 20-fold improvement in the cytotoxicity of free DOX. (B)
The time-dependent viability of Hep3B (■ = 24 hours, ■ = 7 days) and hepatocytes (■ = 24 hours, ■ = 7
days) after exposure to free DOX, as well as DOX encapsulated in SP94-targeted VLPs. VLPs of Qβ
bacteriophage are inherently more stable than MS2 VLPs due to the presence of disulfide bonds in their
protein capsids; therefore DOX-loaded Qβ VLPs minimize the long-term loss of hepatocyte viability while
effectively killing MDR Hep3B. All error bars represent 95% confidence intervals (1.96 σ) for n = 5.

SP94-Targeted MS2 VLPs that Encapsidate a Cocktail of siRNA Induce RNAiMediated Growth Arrest and Apoptosis of HCC. Due to their ability to spontaneously
self-assemble in the presence of nucleic acids, MS2 VLPs are natural carriers of antisense
oligonucleotides, small interfering RNA (siRNA), microRNA (miRNA), ribozymes,
RNA decoys, aptamers, etc. and can potentially be adapted to encapsulate DNA vectors
that encode therapeutic RNAs. RNA interference (RNAi) has been widely used to
suppress expression of various proteins necessary for cancer cell proliferation and
survivability via sequence-specific, post-transcriptional gene silencing that is typically
mediated by siRNA or miRNA(87, 88). siRNAs (~21-base-pair segments of doublestranded RNA) are attractive as anti-cancer agents given their ability to promote RNAi in
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mammalian cells without eliciting an interferon response (89). Furthermore, Davis, et al.
recently demonstrated that siRNA, upon systemic administration via Tf-targeted
polymeric nanoparticles can effectively inhibit specific genes in humans with solid
tumors(3). Thus, targeted delivery of siRNA shows great promise in effectively treating
a variety of cancers(90).
siRNA-driven formation of MS2 VLPs results in a > 90% yield of fullyassembled capsids, nearly 100% of which encapsidate 94 ± 6 siRNA molecules. siRNAloaded MS2 VLPs are stable for > 3 months and effectively protect encapsidated siRNA
from RNase-mediated degradation (data not shown). SP94-targeted MS2 VLPs that
encapsidate a cocktail of siRNA that silences expression of cyclin A2, cyclin B1, cyclin
D1, and cyclin E1 induce selective growth arrest and apoptosis of Hep3B at
concentrations < 100 pM. The upregulation and activation of certain cyclins and cyclindependent kinases (Cdk), including cyclin A, cyclin D1, cyclin E, and Cdk4, have been
implicated in hepatocarcinogenesis(91), and siRNA-mediated silencing of cyclin B1 and
cyclin E has been demonstrated to enhance the susceptibility of various cancer types to
chemotherapeutic drugs, as well as to induce selective growth arrest and apoptosis (9294). SP94-targeted VLPs loaded with a siRNA that induces sequence-specific
degradation of cyclin A2, cyclin B1, cyclin D1, or cyclin E1 mRNA cause a dosedependent (Fig. 4A) and time-dependent (Fig. 4B) decrease in expression of the target
protein upon exposure to Hep3B. The concentrations of siRNA necessary to silence 90%
of cyclin A2, cyclin B1, cyclin D1, and cyclin E1 expression (IC90) when delivered to
Hep3B via SP94-targeted VLPs are 152 ± 4.3 pM, 164 ± 2.5 pM, 171 ± 3.9 pM, and 201
± 7.8 pM, respectively (Fig. 4A), all of which correlate well to IC90 values obtained using
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commercially-available transfection reagents (Fig. S5A). As compared to non-specific
transfection reagents composed of cationic lipids (e.g. LipofectamineTM RNAiMAX),
however, SP94-targeted VLPs are capable of selectively delivering siRNA cocktails to
Hep3B without affection protein levels in hepatocytes (Fig. S5B). Exposure of Hep3B to
the concentration of SP94-targeted VLPs necessary to reach the IC90 value for a
particular target protein causes a 90% reduction in protein expression within 48 hours
(Fig. 4B), an effect that persists for nearly a week and can be prolonged via modification
of

siRNA

with

a

nuclear

localization

sequence

(H2N-

NQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY-COOH, derived from
the M9 domain of heterogeneous nuclear ribonucleoprotein A1(95)) (Fig. S5C). SP94targeted MS2 VLPs that encapsidate the siRNA cocktail induce G0/G1 arrest (Fig. 4C)
and apoptosis (Figs. 4D and S5E) in 90% of Hep3B within 72 hours at a total siRNA
concentration of 100 pM without affecting the viability of hepatocytes (Figs. 4D and
S5F).
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Figure 4. MS2 VLPs are natural carriers of small interfering RNA (siRNA) and modification of the capsid
with the SP94 peptide enables specific delivery of siRNA cocktails that silence expression of various
cyclins to Hep3B, causing rapid growth arrest and apoptosis at picomolar concentrations. (A) and (B)
siRNAs that silence expression of cyclin A2 (●), cyclin B1 (○), cyclin D1 (▼), or cyclin E1 (Δ), when
delivered to Hep3B via SP94-targeted VLPs, cause a dose- (A) and time-dependent (B) decrease in protein
concentrations, as determined by immunofluorescence. (C) SP94-targeted VLPs that encapsidate a siRNA
cocktail (silences expression of cyclin A2, cyclin D1, and cyclin E1; 100 pM total concentration) induce
proliferation arrest, as determined by BrdU incorporation, and G0/G1 arrest, as determined by Hoechst
33342 staining, in Hep3B within 72 hours. (D) SP94-targeted VLPs that encapsidate a siRNA cocktail
(silences expression of cyclin A2, cyclin B1, cyclin D1, and cyclin E1; 100 pM total concentration) induce
apoptosis in Hep3B (▼ = total number of apoptotic cells) but not hepatocytes (Δ) within 48 hours. Early
apoptosis (● = cells positive for Alexa Fluor® 488-labeled annexin V) is induced in Hep3B within 12 hours,
and late apoptosis (○ = cells positive for annexin V and propidium iodide) is induced within 24-48 hours.
All error bars represent 95% confidence intervals (1.96 σ) for n = 5.

Ricin A-Chain Can Induce Specific Intoxication of HCC at Femtomolar
Concentrations when Delivered via SP94-Targeted VLPs. MS2 VLPs can stably
encapsidate RNA-modified cargo within their interior volume, which protects cargo from
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degradation and prevents toxicity to non-target cells and tissues. MS2 VLPs modified
with high densities of targeting ligands can, furthermore, bind to and be internalized by
cancer cells with high specificity. The combined stability and targeting efficacy of MS2
VLPs has enabled their development as a delivery vehicle for especially cytotoxic agents,
such as the A-chain of ricin toxin (57). Ricin is a potent protein toxin derived from the
seeds of Ricinis communis and exerts its cytotoxic effect via catalytic inhibition of
protein synthesis. Native ricin is a heterodimer composed of the catalytically-active Achain (32 kDa), which inhibits eukaryotic ribosomes via depurination of a single adenine
residue (A4324) in 28S RNA, and the galactose-binding B-chain (32 kDa), which utilizes
its lectin activity to promote receptor-mediated endocytosis of the toxin (96, 97).
We have demonstrated that ricin A-chain, when encapsidated within SP94targeted MS2 VLPs, induces caspase-3-dependent apoptosis of Hep3B at a concentration
of 100 fM while maintaining nearly 100% hepatocyte viability. SP94-targeted VLPs
loaded with ricin A-chain cause a dose-dependent (Fig. 5A) and time-dependent (Fig. 5B)
decrease in nascent protein synthesis upon exposure to Hep3B. The concentration of ricin
A-chain-loaded VLPs necessary to cause a 90% reduction in Hep3B protein biosynthesis
within 48 hours is 98.9 ± 3.8 fM (Fig. 5A). The SP94 peptide, when displayed in high
densities on MS2 VLPs, confers the specificity necessary to promote selective protein
inhibition in HCC without affecting protein levels in hepatocytes (Fig. S6A). In
comparison, monomeric ricin A-chain is unable to penetrate cells and, therefore, has no
effect on Hep3B or hepatocyte protein synthesis, while ricin A-chain-loaded MS2 VLPs,
when modified with a peptide (octaarginine, or R8 (98)) that promotes non-specific
macropinocytosis, induce rapid protein inhibition when exposed to both Hep3B and
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hepatocytes (Fig. S6A). In addition to inhibiting nascent protein synthesis, SP94-targeted
MS2 VLPs that encapsidate ricin A-chain induce caspase-3-dependent apoptosis in
Hep3B at exceedingly low concentrations (~100 fM) without affecting the viability of
hepatocytes (Fig. 5C). Furthermore, apoptosis occurs rapidly; 90% of Hep3B cells are
dead within 72 hours of being exposed to ricin A-chain-loaded VLPs (Fig. 5D). In order
for SP94-targeted VLPs to effectively induce apoptosis in Hep3B, however, they must be
co-modified with the H5WYG fusogenic peptide, which promotes endosomal escape of
endocytosed VLPs and prevents lysosomal degradation of encapsidated ricin A-chain
(Fig. S6B); agents that inhibit lysosome acidification, such as chloroquine, promote
cytotoxicity of ricin A-chain-loaded VLPs in the absence of H5WYG. In conclusion,
MS2 VLPs modified with a high density of the SP94 targeting peptide are able to
selectively deliver a high payload of various therapeutic and diagnostic agents to HCC
without affecting the viability of non-transformed cells. MS2 VLPs are ideally suited for
targeted delivery of siRNA cocktails and possess the specificity and stability necessary to
transport highly cytotoxic agents.
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Figure 5. VLPs bearing the SP94 targeting peptide deliver ricin A-chain to HCC with high enough
specificity to induce rapid apoptosis in Hep3B while leaving hepatocytes unharmed. (A) and (B) Ricin Achain enzymatically inhibits 28S ribosomes and is, therefore, highly toxic to mammalian cells in minute
quantities. Ricin A-chain cannot transverse the cell membrane unaided, however. SP94-modified VLPs
encapsidate an average of 21 molecules of ricin A-chain per VLP and cause a 90% decrease in nascent
protein synthesis (as measured by a decrease in the incorporation of a fluorescently-labeled derivative of
methionine) at a concentration ~100 fM (A) within 48 hours (B). (C) Targeted VLPs that encapsidate ricin
A-chain induce activation of caspase-3 in 90% of Hep3B cells at a concentration of 100 fM. (D) Ricin Achain delivered to Hep3B via targeted VLPs induces activation of caspase-9 and caspase-3 within 12-24
hours. Hepatocytes remain unaffected, even after being exposed to ricin A-chain-loaded VLPs for >2
weeks. All error bars represent 95% confidence intervals (1.96 σ) for n = 5.
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Materials and Methods
Synthesis of MS2 VLPs Loaded with Various Cargos
MS2 and Qβ bacteriophages were produced by infecting E. coli A/λ using wellestablished procedures(64) and purified by sedimentation to equilibrium in CsCl density
gradients. To harvest coat protein for reassembly reactions, phages were diluted 1:3 in
glacial acetic acid, incubated on ice for two hours, centrifuged briefly to pellet
precipitated RNA and maturase, and dialyzed against 20 mM acetic acid for 20 hours.
Modification of cargo with the pac site and/or fluorescent labels was performed as
described in the Supplementary Materials and Methods section. Briefly, drug-pac site
conjugates were made by adding an excess of doxorubicin and/or cisplatin to the pac site
(containing either a 3’ sulfhydryl moiety or modified with three internal 5-fluorouridines
and a 5’ thiol), pre-activated with LC-SPDP per manufacturer’s instructions; unreacted
drugs were removed via dialysis. To prepare quantum dot-pac site conjugates, aminefunctionalized quantum dots were combined with an excess of LC-SPDP-activated pac
site (modified with a 3’ sulfhydryl moiety). Unreacted RNA was removed using a
centrifugal filter device (50 kDa MWCO). Ricin A-chain-pac site conjugates were
synthesized by activating reduced ricin A-chain with LC-SPDP, adding an excess of the
pac site (containing a 3’ amine moiety), incubating at 4°C for 24 hours, and removing
unreacted RNA via centrifugal-driven filtration (10 kDa MWCO). A typical reassembly
reaction consisted of 0.01 - 1 mM siRNA or pac site-modified cargo in 1X PBS, to which
a 10-fold molar excess of dimerized coat protein was added. Reassembly was allowed to
proceed for 4 hours at room temperature and 48 hours at 4°C prior to purification of
excess coat protein and unencapsidated cargo via size-exclusion chromatography. VLPs
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were modified with targeting ligands by incubating an excess of the ligand with
SM(PEG)24–activated capsids overnight at 4°C and removing unreacted ligand using a
centrifugal filtration device (100 kDa MWCO). Average peptide density was determined
using Tricine SDS-PAGE, while average Tf and CHALV-1 density was determined via
Laemmli SDS-PAGE(99). ImageJ Image Processing and Analysis Software was utilized
to compare band intensities relative to a standard concentration curve.

Determination of Dissociation Constants
Various concentrations of monovalent peptides (labeled with Alexa Fluor® 555 C2
maleimide) or VLPs (labeled with Alexa Fluor® 555 carboxylic acid succinimidyl ester)
were incubated with 1 x 106 cells/mL for 1 hour at 4°C. Unbound ligands and VLPs were
removed via centrifugation, cells were resuspended in serum- and phenol red-free growth
medium, and samples were analyzed with a FACSCalibur flow cytometer; fluorophores
were excited with the 488-nm laser source, and emission was collected in the FL2
channel (585/42 filter/bandpass). Mean fluorescence intensity (MFI) was determined
using FlowJo Software, and GraphPad Prism was employed to generate saturation
binding curves (ligand or VLP concentration versus MFI), subtract the contribution of
non-specific binding (i.e. binding of unmodified VLPs or VLPs modified with a control
peptide) from total binding (i.e. binding of SP94-targeted VLPs), and calculate Kd values.

Preparation of Confocal Fluorescence Microscopy Samples
1 x 104 – 1 x 106 cells/mL were seeded on sterile coverslips (25-mm, No. 1.5) coated with
0.01% poly-L-lysine (150-300 kDa) and allowed to adhere for 4-24 hours at 37°C. Cells
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were incubated with a 2000-fold excess of SP94-targeted VLPs for 1-4 hours at 37°C,
washed with 1X PBS, stained according to manufacturer’s instructions, fixed with 3.7%
formaldehyde (10 minutes at room temperature), and mounted with an anti-fade reagent
(SlowFade® Gold). Cells stained via immunofluorescence were, after fixation,
permeabilized with 0.2% Triton X-100 (5 minutes at room temperature) and incubated
with a blocking agent (Image-iT FX signal enhancer) for 30 minutes at room
temperature; primary antibodies and secondary antibodies were diluted 1:500 in PBS
with 1% BSA and incubated with cells for 1 hour at 37°C.

Viability and Apoptosis Assays
The viability of cells continually exposed for various time periods to various
concentrations of chemotherapeutic drugs, drug cocktails, and siRNA cocktails was
determined using either SYTOX® Green nucleic acid stain and Alexa Fluor® 647-labeled
annexin V (drugs and drug cocktails) or Alexa Fluor® 488-labeled annexin V and
propidium iodide (siRNA cocktails). Double-negative cells were considered to be viable;
cells in early apoptosis were counted as those positive for annexin V, while cells in late
apoptosis were counted as those double-positive for annexin V and either SYTOX

®

Green or propidium iodide. Activation of caspase-3 and caspase-9 via SP94-targeted
VLPs loaded with ricin A-chain was monitored using CaspGLOWTM staining kits per
manufacturer’s instructions.
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Supplementary Figures and Legends:

A

B

C

D

*

Figure S1. The avidity of MS2 VLPs for HCC is dependent on the inherent affinity of the monovalent
ligand, as well as on the density of ligands displayed on the VLP surface. (A) The average number of
ligands that can be conjugated to a single MS2 VLP under saturating conditions. (B) The dissociation
constants (Kd) of monovalent ligands (■) and MS2 VLPs modified with the maximum ligand density (■)
when exposed to Hep3B. (C) Kd values of MS2 VLPs, when modified with the maximum ligand density,
for Hep3B (■), PLC/PRF/5 (■), HepG2 (■), and hepatocytes (■). (D) The Kd values of SP94-targeted MS2
VLPs (modified with an average of 240 peptides per VLP) for Hep3B and hepatocytes when VLPs are
either unmodified (■) or surface-modified with PEG (■). * indicates that the values are NOT significantly
different (using ANOVA, p ~ 0.50 for n = 5). All error bars represent 95% confidence intervals (1.96 σ) for
n = 5.
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Hep3B

Hepatocytes

Figure S-2. MS2 VLPs modified with a high density (~240 peptides per VLP) of the SP94 targeting
peptide can bind specifically to Hep3B cells even when they are co-cultured with hepatocytes. Alexa
Fluor® 488-labeled CHALV-1 specifically recognizes and binds to HCC.
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VLPs and LAMP-1
r = 0.67 +/- 0.09

VLPs and Rab11
r = -0.12 +/- 0.08

DIC

Merge

Figure S-3. MS2 VLPs modified with the SP94 targeting peptide are directed to lysosomes upon
endocytosis by HCC. A saturating concentration of SP94-targeted VLPs, labeled with Alexa Fluor® 555
(red), was exposed to sub-confluent Hep3B cells for 2 hours at 37°C. The cells were then washed, fixed,
permeabilized, and exposed to an Alexa Fluor® 488-labeled antibody against lysosome-associated
membrane protein-1 (LAMP-1, green) and an Alexa Fluor® 647-labeled antibody against Rab11a (white).
The positive Pearson’s correlation (r) that exists between SP94-targeted VLPs and LAMP-1 indicates that
VLPs are directed to lysosomes upon endocytosis by Hep3B. Conversely, the near-zero Pearson’s
correlation that exists between SP94-targeted VLPs and Rab11 indicates that VLPs are not localized within
Rab11+ recycling endosomes. Differential Interference Contrast (DIC) images were employed to define the
boundaries of Hep3B cells, the nuclei of which are labeled with DAPI, such that pixels outside of the cell
boundaries could be disregarded when calculating Pearson’s correlation coefficients (expressed as the mean
value ± the standard deviation for n = 3 x 50 cells). Scale bars = 10 µm.
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Figure S-4. Upon endocytosis, MS2 VLPs co-modified with the SP94 targeting peptide and the H5WYG
fusogenic peptide become distributed in the cytosol of HCC cells. (A) SP94-targeted MS2 VLPs, labeled
with Alexa Fluor® 555 (red), are rapidly endocytosed by Hep3B (t½ = 6 minutes). (B) VLPs co-modified
with the SP94 and H5WYG peptides become distributed in the cytosol of Hep3B cells within 1-4 hours of
endocytosis. Hep3B cells are labeled with Hoechst 33342 and CellTrackerTM Green CMDFA. Scale bars =
10 µm.
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Figure S-5. SP94-targeted MS2 VLPs, when loaded with a siRNA cocktail that silences expression of
cyclin A2, cyclin B1, cyclin D1, and/or cyclin E1, can induce selective apoptosis of Hep3B without
affecting the viability of hepatocytes. (A) The concentration of siRNA necessary to silence 90% of cyclin
A2, cyclin B1, cyclin D1, or cyclin E1 expression (IC90) in Hep3B when delivered via SP94-targeted MS2
VLPs (■) or LipofectamineTM RNAiMAX (■). (B) The percentage of initial cyclin A2 expression that
remains upon exposure of Hep3B (■) and hepatocytes (■) to LipofectamineTM RNAiMAX (LFA) with
encapsulated siRNA or SP94-targeted VLPs with encapsulated siRNA. Cyclin A2 expression is unaffected
by SP94-targeted VLPs, unmodified VLPs with encapsulated siRNA, and siRNA alone. (C) The timedependent change in cyclin A2 expression after exposure of logarithmic (●) or confluent Hep3B (○) to
SP94-targeted, siRNA-loaded VLPs for 24 hours. The duration of cyclin A2 silencing can be increased via
modification of the siRNA with a nuclear localization sequence (NLS); cyclin A2 concentrations remain at
less than 50% of initial values for 14 days in logarithmic Hep3B (▼) and for 28 days in confluent Hep3B
(Δ) using this strategy. (D) NLS-modified siRNA (■) can, when delivered to logarithmic Hep3B via SP94targeted MS2 VLPs, suppress Hep3B division for longer periods of time than unmodified siRNA (■). (E)
and (F) SP94-targeted VLPs, when loaded with the siRNA cocktail, can induce apoptosis of Hep3B (E)
without affecting the viability of hepatocytes (F). Within several minutes, MS2 VLPs, labeled with Alexa
Fluor® 647 (white), are endocytosed by Hep3B. Within several hours, VLPs become distributed in the
cytosol of Hep3B cells and release their encapsidated siRNA. Early apoptosis (determined using Alexa
Fluor® 488-labeled annexin V) is induced within 24 hours, while late apoptosis (determined using
propidium iodide) is induced within 72 hours. The nuclei of Hep3B and hepatocytes are labeled with DAPI.
All scale bars = 20 µm. All error bars represent 95% confidence intervals (1.96 σ) for n = 3.
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Figure S-6. MS2 VLPs, when modified with the SP94 targeting peptide, possess the specificity to deliver
ricin A-chain to Hep3B without affecting the viability of hepatocytes. (A) The percentage of initial nascent
protein synthesis that remains upon exposure of Hep3B (■) and hepatocytes (■) to ricin A-chain-loaded
VLPs modified with either the SP94 peptide or the R8 peptide. SP94-modified VLPs, R8-modified VLPs,
unmodified VLPs loaded with ricin A-chain, and ricin A-chain alone have no affect on protein biosynthesis
in either Hep3B or hepatocytes. (B) The percentage of apoptotic Hep3B (i.e. cells that are positive for
caspase-3 activation) increases dramatically when VLPs co-modified with the SP94 targeting peptide and
the H5WYG fusogenic peptide are utilized to deliver ricin A-chain. Endosomal escape of ricin A-chain
loaded VLPs is critical to promote apoptosis of Hep3B, as evidenced by the relative inability of SP94targeted VLPs loaded with ricin A-chain to induce caspase-3 activation; the activity of these VLPs can,
however, be recovered by inhibiting lysosomal acidification via exposure of Hep3B to chloroquine. (C) –
(E) SP94-targeted, ricin A-chain-loaded VLPs, labeled with Alexa Fluor® 647 (white), are rapidly
endocytosed by Hep3B (C) and induce selective apoptosis, as evidenced by caspase-3 and caspase-9
activation, within 72 hours (D). SP94-targeted VLPs that encapsidate ricin A-chain do not affect the
viability of hepatocytes even after continual exposure for 7 days (E). Hep3B and hepatocyte nuclei are
labeled with DAPI. All scale bars = 20 µm. All error bars represent 95% confidence intervals (1.96 σ) for n
= 3.

81

CHAPTER 3

In-situ Grazing Incidence Small Angle X-ray Scattering of 2D
Virus-Like Particle Lattice Formation via a Convective
Assembly Process
The use of viral particles (including icosahedral and filamentous bacterial phages, as well
as plant viruses1) as building blocks or scaffolds in the synthesis of nanoscale materials
presents several distinct advantages over the use of ‘artificial’ nanoparticles, including
perfect monodispersity, convenience of synthesis from laboratory culture, and, most
importantly, the range of strategies available to selectively modify the viral structure with
organic or inorganic substances, including the encapsidation of nanoparticles2 or other
foreign materials within the internal volume of the particle and the conjugation of
functional peptides (either through chemical reaction or genetic engineering) to
selectively bind or nucleate the growth of inorganic materials at the surface of the viral
capsid1, 3, 4. By combining these particle modification approaches with ‘bottom-up’ selfassembly, viral particles could, in principle, be used as scaffolds, templates, or
‘nanocontainers’ to organize virtually any type of functional inorganic material into
larger hierarchical structures relevant to energy transduction, sensing, information
storage, logic devices, etc.1-4 Synthesis of these assemblies will require a continuous
coating method applicable to large-scale solid substrates; although 3D crystallization5,
liquid crystal organization6-8, and interfacial assembly9-11 of viral particles has been
investigated as means of viral lattice formation, convective assembly12-17 (CA) has
emerged as a promising tool for the rapid, generalized deposition of colloidal assemblies
directly onto a solid surface. In CA (Figure 1), a film is deposited from a microliter-sized
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droplet of a colloidal suspension trapped between a fixed substrate and a plate moving at
constant velocity v across the substrate at a fixed angle θ (typically < 30° with respect to
one another). Although originally developed for spherical colloids, CA has since been
applied to ordered arrays of tobacco mosaic virus (TMV), a rod-like plant virus with
diameter of ca. 18 nm and length of approximately 300 nm17; here, we extend this
method to viral particles with icosohedral symmetry, specifically virus-like particles
(VLPs, capsids assembled from viral coat protein without the presence of genetic
material) derived from the bacteriophages MS2 and Qβ (Figure 2), and examine the
mechanism of lattice formation during CA using in-situ grazing-incidence small-angle xray scattering (GISAXS) performed at a synchrotron source. Icosohedral viruses and
VLPs present a number of advantages as nanoscale building blocks arrays over TMV or
other filamentous phages, including almost spherical symmetry and near perfect
monodispersity enabling the assembly of highly ordered crystalline lattices9-11, ability to
produce VLPs from plasmids in E. coli in large quantities18, and availability of improved
genetic screens and selections19 relative to those available for rod-like viruses that could
eventually allow the identification of mutants with altered interaction potentials or the
ability to direct specific growth of inorganic materials. Furthermore, GISAXS enables

Figure 1. Schematic of the convective assembly process used in GISAXS studies of VLP self-assembly.
A plate at angle θ is moved across a substrate at velocity v, trailing a meniscus from which a particle film
is deposited. The self-assembly process is observed at a fixed position on the substrate
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the in-situ characterization of nanostructure during dynamic assembly processes in realtime under an ambient environments20-22, unlike electron microscopy (a technique
generally limited to ex-situ studies20, 23-25) or optical methods. In GISAXS, an x-ray beam
is incident upon a sample at an angle greater than the critical angle of the film but less
than that of the substrate, thus maximizing the scattering volume inside the film and,
coupled with the high photon flux obtained at a synchrotron source, enabling the
investigation of fast (on the time scale of seconds) self-assembly phenomena of films as
thin as one monolayer

20

. For the study of CA, the x-ray beam is placed at a fixed

position upon the solid substrate (Figure 1); the film assembly process is monitored as the
plate of the convective coater passes through this spot.
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Figure 2. Structures of Qβ (a) and MS2 (b) bacteriophages, and close-ups of phage subunit structure for
Qβ (c) and MS2 (d). Acidic and basic amino acid residues are highlighted in red and blue, respectively,
with hydrophobic loops in black.

Our initial studies compared the CA of VLPs derived from MS2 and Qβ (Figure
2). MS2 and Qβ are nearly identical in size (27. 5 nm and 28.5 nm, respectively), but
differ in overall surface charge charge (3.9 vs. 5.3 for MS2 and Qβ at a pH of 7.2), charge
distribution (both across the surface and radially from the center of the particle), and
acidity (with isoelectric points of 3.9 and 5.3 for MS2 and Qβ). As seen in the time
sequence

in-situ

GISAXS

data

in

Figure
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3,

these

differences

result

in

Figure 3. Time sequence of GISAXS data, referenced to the first emergence of the x-ray beam from
behind the plate of the convective coater (panels a and e), comparing the self-assembly of Qβ (a-d)
and MS2 (e-h) from 100mM NaCl under identical coating conditions. For Qβ, assembly of 2D arrays
occurs without intermediate aggregation or structure (b-c); disappearance of (20) and (21) reflections
indicates loss of long-range order during film drying (d). MS2 assembly is characterized by formation
of multilayer aggregates (g) which are deposited as a glassy film with poor translational order(h).
Plate movement is from left to right in both series of images.

dissimilar self-assembly behavior. In this data, time referenced to the first appearance of
a particle array (panels b and f), initial scattering for both particle types is dominated by a
low-angle reflection from the curved liquid meniscus and glass slide of the convective
coater (panels a and b); a set of cross-hatched scattering features also appears (most
notably in the data set for MS2), a feature that we do not attribute to any self-assembly
process given the symmetry of these features with the background reflection. For Qβ, the
self-assembly process can be divided into two stages; direct appearance (panel b) and
evolution (panel c), notably without any intermediate structure, followed by a reduction
in film ordering from water evaporation (panel d).

However, MS2 assembly is

characterized by the formation of multilayer aggregates (panels f and g), as evidenced by
the inward curvature of the scattering features along the substrate axis; this aggregation is
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Figure 4. a) A horizontal linecut at qz= 0.24  0.02 nm-1 taken from the GISAXS data for Qb selfassembled in water at t=19 (the dashed line marked in Figure 3c). The first four Bragg diffractions are
indexed to 2D hexagonal packing. b) The time evolution of this horizontal linecut. c) The ratio of the
integrated intensities underneath the (11) and (10) reflections, after background subtraction. The red
line is a fit to an exponential decay function as described in the text, and the inset represents the
dominant 2D domain orientation induced by convective transport. (d)-(f) are corresponding panels
from GISAXS for Qb in water with 10% glycerol.

intensified after complete film drying (panel h), resulting in a glassy film without longrange order.

This propensity toward aggregation for MS2 is a result of the ionic

properties of this particle, a conclusion supported by assembly as a function of ionic
strength (vide infra).Data for Qβ assembly was analyzed in further detail as presented in
Figure 4a-c. Line cuts plotted as a function of time (panel b) show a broadening of the
(10) diffraction peak as well as a shift to higher q during film drying.. The (10) peak
shape analysis in the beginning at t=19 sec shows a lattice constant of 24.2 nm (giving an
interparticle spacing of 24.2*(2/sqrt(3)) = 28.0 nm, consistent with the size of Qβ) with a
domain size of ~280 nm. Similar analysis near the end at t=162 sec shows a contracted
packing of lattice constant of 22.3 nm (an interparticle distance of 25.7 nm) and an
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average domain size of ~158 nm. We attribute this shrinkage in interparticle spacing
during film drying to collapse of the (empty) VLP capsid. The average number of
particles per domain also decreases by 60% during film drying, from ca. 130 at t = 19 sec
to ca. 50 at t = 162 sec).
Figure 4c plots the intensity ratio of (11) and (10) reflections from the data in
panel b. From this data, it is apparent that convective transport favors an orientation of
the self-assembled domains with (11) direction parallel to the direction of the plate
motion.

This initial lattice orientation is consistent with an assembly mechanism

whereby convective transport of particles toward a drying front, induced by water
evaporation, is combined with immersion capillary forces to guide the packing of
colloidal particles into a 2D lattice26. The observed reorientation of lattice domains after
assembly demonstrates that the film maintains fluidity over a time scale sufficient for
structural rearrangement in the film, either by rotation of entire lattice domains or
diffusion of individual particles; the presence of either process suggests incomplete
surface coverage of the 2D viral array. This thermal diffusion can be fit to an exponential
decay of the form of I11 I10  C1  C2 e t  , giving a characteristic time scale  of 263
sec, consistent with the onset time of 31 sec (labeled as blue arrow c) for this diffusion
mechanism to dominate the average orientation of the VPL domains. The peak intensity
ratio saturates at a value of C1  0.47 , slightly smaller than 0.58 estimated from the
simulations for randomly orientated 2D domains modeled using paracrystal theory,27 an
effect we attribute to the form factor of the VLP particles.
In contrast to Qβ assembly from H2O, Qβ self-assembled in 10% glycerol has a
nearly constant lattice parameter of 24.4 nm (inter-particle distance is 28.2 nm), and
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Figure 5. a-c) Time sequence in-situ GISAXS data for the convective assembly of MS2 onto an
amine-modified surface, with initial appearance of the MS2 lattice (a) followed by development of
lattice order (b) and ultimate collapse after film drying (c). d) Lattice spacing for the (10) reflection
as a function of time for MS2 assembled at an amine or carboxylate-terminated SAM, e) as d, but for
Qβ.

much better degree of ordering, seen as much sharper diffractions in (d) and (e).
However, the observed FWHM of the diffraction are limited by our instrument
resolutions of ~0.01 nm-1, which indicates an averaged domain size beyond ~600 nm.
Furthermore, the ratio of (10) to (11) intensity is constant over time (Figures 4e and f),
with a value that suggests formation of random domain orientation within the film. We
posit that lack of favored domain orientation, along with the increased long-range order
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relative to films deposited from 100 mM NaCl, is a result of a fundamentally different
mechanism for lattice assembly; specifically, we hypothesize a self-assembly mechanism
where convective flow at the drying line is negligible due to an increase in viscosity in
the coating solution after preferential evaporation of water as well as the inherent low
volatility of glycerol. Instead, transport of particles to the growing lattice is controlled by
2D diffusion, with the implication that diffusion-controlled transport results in greater
long-range order of the 2D crystal. We note that mobility at the substrate surface due to
the presence of a non-volatile medium cannot account for the increased order alone, as
the rearrangement of lattice orientation seen in films deposited from 100 mM NaCl
indicate significant surface mobility of particles without glycerol over the time frame of
film formation. Another factor that may influence the degree of long-range order in
assemblies of viral particles between glycerol and aqueous solutions is the Debye length
of the virus. However, variation of the Debye length for Qβ during self-assembly by
variation of the NaCl concentration (from 0.1 to 1.0 M) did not show any increase in the
degree of long-range ordering, suggesting that for Qβ electrostatic screening is not a
significant factor in lattice formation, again consistent with convective transport
dominating

the

self-assembly

process

from

aqueous

solutions26.

Reduction in immersion capillary forces during the 2D crystallization process between
particles in water versus particles in glycerol may play a role in increased lattice ordering,
although the reduction in interparticle force in the latter case is expected to be only ca.
13%26.
Finally, we utilized our in-situ GISAXS studies of VLP assembly to identify
experimental conditions under which the aggregation of MS2 is reduced during the self90

assembly process, enabling the assembly of ordered 2D lattices using convective
assembly.

According to DLVO (Derjaguin-Landau-Verwey-Overbeek) theory28-30,

aggregation driven by van der Waals forces can be lessened by increasing the
electrostatic repulsion between particles through reduction of the ionic strength of the
supporting medium, or by increasing the surface potential of the particles31. Consistent
with these predictions, a study of assembly from NaCl solutions with ionic strengths
between 0.10 to 1.0 M found that aggregation of MS2 was eliminated for NaCl
concentrations below 100 mM, forming ordered 2D lattices.

Assuming a 10-fold

concentration of electrolyte at the point of MS2 aggregation, this corresponds to a Debye
length of ca. 1 nm, on the same length scale as the peptide loops extending from the
surface of MS2. Similarly, increasing the surface potential of MS2 by addition of surface
charge through chemical conjugation with decamers of the cationic peptides poly-Llysine or poly-L-arginine inhibited aggregation of MS2, permitting the assembly of 2D
close-packed lattices from 100 mM NaCl onto oxidized silicon.
Assembly onto amine- or carboxylate- modified surfaces was also found to reduce
aggregation of MS2 while altering the self-assembly pathway for both MS2 and Qβ VLPs
relative to that seen for lattice formation at oxidized silicon. Example in-situ data for
MS2 assembly at an amine-modified self-assembled monolayer (SAM) is shown in Fig.5
panels a-c; data for assembly at a carboxylic-acid terminated interface as well as for Qβ
at either surface is qualitatively similar. We find that lattice development at a modified
substrate differs in several important respects over that seen at an unmodified (silica)
surface. First, ordering in MS2 arrays is increased relative to that seen at unmodified
surfaces under identical solution conditions as evidenced by the appearance of a (20)
91

reflection (Fig. 5b). Unlike assembly of Qβ at unmodified surfaces, the I11/I10 ratio for
both MS2 and Qβ is constant throughout the entire film formation process (equal to ca.
0.4, consistent with isotropic ordering of lattice domains in the plane of the substrate)
until complete film drying induces collapse of the VLP lattice (Fig. 5c). However, there
are significant changes in lattice spacing over time; as seen in Figs. 5d and e for MS2
and Qβ, respectively, the (10) interplanar spacing undergoes expansion from an initial
compacted state (with this effect much more pronounced for Qβ than MS2) followed by
shrinkage of the lattice during film drying (as was seen for Qβ assembly at silicon) and,
in the case of MS2, complete collapse of the film into a glassy state (Fig. 5c).
Furthermore, (10) spacing indicates that the initial VLP lattice is compressed by ca. 20%
in the plane of the substrate; while the Qβ interparticle distance recovers to
Based upon this data, we posit a mechanism for VLP assembly at an amine- or
carboxylate-modified surface whereby the initial VLP lattice is not formed by convective
transport (as evidenced by the isotropic lattice orientation ), but rather by adsorption of
VLP to the SAM surface at a point prior to the emergence of the x-ray beam from behind
the coater meniscus, with the formation of an ordered MS2 lattice suggesting that this
adsorption occurs before solvent evaporation increases the VLP concentration to a point
where MS2 aggregation is induced. During the adsorption step, the VLP capsid is
compressed; expansion of the interparticle distance during film drying demonstrates
fluidity in the adsorbed VLP monolayer.

For MS2, the presence of an ordered is

temporary, with complete film drying prompting lattice collapse via aggregation.
In conclusion, we have demonstrated the formation of well-ordered 2D crystals of
empty viral capsids though a convective coating technique, following the self-assembly
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process in real time using grazing-incidence small-angle x-ray scattering at a synchrotron
source. The assembly mechanism is consistent with convective transport of particles to
the drying front of the evaporating film; scrambling of lattice orientation after the initial
assembly stage shows the presence of fluidity in the VLP monolayer. Addition of nonvolatile solvent to the VLP solution increases domain size, with an invariant average
lattice orientation suggesting that assembly does not occur through convective transport,
but possibly by particle diffusion within the deposited film.

Although 2D lattice

formation of MS2 was suppressed by solution aggregation under conditions that
otherwise led to well-defined crystallization of Qβ, using DLVO theory we identified
experimental parameters that can be modified to inhibit VLP aggregation (ionic strength
of the solution, MS2 surface potential), and confirmed the formation of ordered MS2
lattices under these conditions.

Methods MS2 and Qβ bacteriophages were produced by infection of Escherichia coli
A/λ using standard methods32 and purified by sedimentation to equilibrium in CsCl
gradients. Virus-like particles were produced from the parental bacteriophage via
incubation in pH 11.8 buffer for 4 hours, which hydrolyzes the RNA genome and results
in empty capsids. VLPs were stored in TNME buffer (10 mMTris-HCl, 100 mM NaCl,
0.1 mM MgSO4, and 0.01 mM EDTA at pH 7.4) at 4°C. The following conditions were
employed in all GISAXS measurements: particle volume fraction (φ) = 0.02, deposition
velocity (v) = 12 μm/s, relative humidity during the coating process = 15%. C-terminal
cysteine residues of -L-lysine or poly-L-arginine were chemically conjugated to surface
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lysine residues present in the MS2 capsid using a heterobifunctional crosslinker; each
MS2 particle was estimated to bear 120 copies of poly(Lys) or poly(Arg).
GISAXS measurements were performed on beam line 8-ID at the Advanced
Photon Source at Argonne National Labs using a wavelength of 1.6868 Å, a sample-todetector distance of either 1580 or 1254 mm, an analysis angle of 0.20°, and a 2048 x
2048 Marr CCD detector. The 100 µm x 50 µm beam was fixed relative to the substrate
(Figure 1), with the beam direction perpendicular to the movement of the coater plate.
Detector images were obtained with a period of 6 seconds, using an integration time of 1
second.
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